View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2020	May 05, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Trading Symbol	ACHC
Entity Registrant Name	Acadia Healthcare Company, Inc.
Entity Central Index Key	0001520697
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $.01 par value
Security Exchange Name	NASDAQ
Entity File Number	001-35331
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-2492228
Entity Address, Address Line One	6100 Tower Circle
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Franklin
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37067
City Area Code	615
Local Phone Number	861-6000
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		88,942,499

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 81,004	$ 124,192
Accounts receivable, net	339,505	339,775
Other current assets	82,443	78,244
Total current assets	502,952	542,211
Property and equipment, net	3,151,739	3,224,034
Goodwill	2,426,700	2,449,131
Intangible assets, net	89,052	90,357
Deferred tax assets	3,307	3,339
Operating lease right-of-use assets	476,028	501,837
Other assets	68,217	68,233
Total assets	6,717,995	6,879,142
Current liabilities:
Current portion of long-term debt	196,072	43,679
Accounts payable	134,693	127,045
Accrued salaries and benefits	114,790	122,552
Current portion of operating lease liabilities	29,671	29,140
Other accrued liabilities	104,358	141,160
Total current liabilities	579,584	463,576
Long-term debt	2,944,820	3,105,420
Deferred tax liabilities	85,405	71,860
Operating lease liabilities	474,746	502,252
Derivative instrument liabilities	9,015	68,915
Other liabilities	126,767	128,587
Total liabilities	4,220,337	4,340,610
Redeemable noncontrolling interests	33,491	33,151
Equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued
Common stock, $0.01 par value; 180,000,000 shares authorized; 87,842,302 and 87,715,591 issued and outstanding at March 31, 2020 and December 31, 2019, respectively	878	877
Additional paid-in capital	2,561,218	2,557,642
Accumulated other comprehensive loss	(493,138)	(414,884)
Retained earnings	395,209	361,746
Total equity	2,464,167	2,505,381
Total liabilities and equity	$ 6,717,995	$ 6,879,142

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	180,000,000	180,000,000
Common stock, shares issued	87,842,302	87,715,591
Common stock, shares outstanding	87,842,302	87,715,591

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019
Income Statement [Abstract]
Revenue	$ 782,810				$ 760,617
Salaries, wages and benefits (including equity-based compensation expense of $4,979 and $6,101, respectively)	440,316				429,579
Professional fees	63,300				57,007
Supplies	31,971				29,957
Rents and leases	20,824				20,307
Other operating expenses	98,529				93,865
Depreciation and amortization	41,680				40,580
Interest expense, net	42,785				48,130
Transaction-related expenses	3,549				4,321
Total expenses	742,954				723,746
Income before income taxes	39,856				36,871
Provision for income taxes	5,789				7,360
Net income	34,067				29,511
Net income attributable to noncontrolling interests	(604)				(40)
Net income attributable to Acadia Healthcare Company, Inc.	$ 33,463	$ (11,254)	$ 42,566	$ 48,140	$ 29,471
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$ 0.38				$ 0.34
Diluted	$ 0.38				$ 0.34
Weighted-average shares outstanding:
Basic	87,765				87,505
Diluted	87,971				87,694

Condensed Consolidated Statements of Income (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Equity-based compensation expense	$ 4,979	$ 6,101

Condensed Consolidated Statements of Comprehensive (Loss) Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 34,067	$ 29,511
Other comprehensive loss:
Foreign currency translation (loss) gain	(122,000)	44,481
Gain (loss) on derivative instruments, net of tax of $16.3 million and $(3.5) million, respectively	43,746	(8,690)
Other comprehensive (loss) income	(78,254)	35,791
Comprehensive (loss) income	(44,187)	65,302
Comprehensive income attributable to noncontrolling interests	(604)	(40)
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.	$ (44,791)	$ 65,262

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686

+ Details

Condensed Consolidated Statements of Comprehensive (Loss) Income (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Gain (loss) on derivative instruments, tax	$ 16.3	$ (3.5)

Condensed Consolidated Statements of Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Earnings (Accumulated Deficit) [Member]
Balance at Dec. 31, 2018	$ 2,333,307	$ 874	$ 2,541,987	$ (462,377)	$ 252,823
Balance, shares at Dec. 31, 2018		87,444,000
Common stock issued under stock incentive plans	293	$ 2	291
Common stock issued under stock incentive plans, shares		149,000
Common stock withheld for minimum statutory taxes	(1,620)		(1,620)
Equity-based compensation expense	6,101		6,101
Other comprehensive income (loss)	35,791			35,791
Net income (loss) attributable to Acadia Healthcare Company, Inc.	29,471				29,471
Balance at Mar. 31, 2019	2,403,343	$ 876	2,546,759	(426,586)	282,294
Balance, shares at Mar. 31, 2019		87,593,000
Balance at Dec. 31, 2018	$ 2,333,307	$ 874	2,541,987	(462,377)	252,823
Balance, shares at Dec. 31, 2018		87,444,000
Common stock issued under stock incentive plans, shares	55,671
Balance at Dec. 31, 2019	$ 2,505,381	$ 877	2,557,642	(414,884)	361,746
Balance, shares at Dec. 31, 2019	87,715,591	87,715,000
Balance at Mar. 31, 2019	$ 2,403,343	$ 876	2,546,759	(426,586)	282,294
Balance, shares at Mar. 31, 2019		87,593,000
Common stock issued under stock incentive plans	68		68
Common stock issued under stock incentive plans, shares		52,000
Common stock withheld for minimum statutory taxes	(356)		(356)
Equity-based compensation expense	4,182		4,182
Other comprehensive income (loss)	(33,031)			(33,031)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	48,140				48,140
Balance at Jun. 30, 2019	2,422,346	$ 876	2,550,653	(459,617)	330,434
Balance, shares at Jun. 30, 2019		87,645,000
Common stock issued under stock incentive plans	154	$ 1	153
Common stock issued under stock incentive plans, shares		10,000
Common stock withheld for minimum statutory taxes	(37)		(37)
Equity-based compensation expense	4,039		4,039
Other comprehensive income (loss)	(48,377)			(48,377)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	42,566				42,566
Balance at Sep. 30, 2019	2,420,691	$ 877	2,554,808	(507,994)	373,000
Balance, shares at Sep. 30, 2019		87,655,000
Common stock issued under stock incentive plans	54		54
Common stock issued under stock incentive plans, shares		60,000
Common stock withheld for minimum statutory taxes	(205)		(205)
Equity-based compensation expense	2,985		2,985
Other comprehensive income (loss)	93,110			93,110
Net income (loss) attributable to Acadia Healthcare Company, Inc.	(11,254)				(11,254)
Balance at Dec. 31, 2019	$ 2,505,381	$ 877	2,557,642	(414,884)	361,746
Balance, shares at Dec. 31, 2019	87,715,591	87,715,000
Common stock issued under stock incentive plans		$ 1	(1)
Common stock issued under stock incentive plans, shares		127,000
Common stock withheld for minimum statutory taxes	$ (1,402)		(1,402)
Equity-based compensation expense	4,979		4,979
Other comprehensive income (loss)	(78,254)			(78,254)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	33,463				33,463
Balance at Mar. 31, 2020	$ 2,464,167	$ 878	$ 2,561,218	$ (493,138)	$ 395,209
Balance, shares at Mar. 31, 2020	87,842,302	87,842

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Consolidated Statements of Cash Flows (Unaudited) $ in Thousands	3 Months Ended
	Mar. 31, 2019 USD ($)
Operating activities:
Net income	$ 29,511
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	40,580
Amortization of debt issuance costs	2,888
Equity-based compensation expense	6,101
Deferred income taxes	(666)
Other	2,187
Change in operating assets and liabilities:
Accounts receivable, net	(11,980)
Other current assets	(5,875)
Other assets	295
Accounts payable and other accrued liabilities	(15,701)
Accrued salaries and benefits	(5,849)
Other liabilities	2,182
Net cash provided by operating activities	43,673
Investing activities:
Cash paid for acquisitions, net of cash acquired	(40,400)
Cash paid for capital expenditures	(69,248)
Cash paid for real estate acquisitions	(1,066)
Proceeds from sale of property and equipment	928
Other	(315)
Net cash used in investing activities	(110,101)
Financing activities:
Borrowings on revolving credit facility	71,573
Principal payments on long-term debt	(8,246)
Common stock withheld for minimum statutory taxes, net	(1,327)
Other	(3,497)
Net cash (used in) provided by financing activities	58,503
Effect of exchange rate changes on cash	1,099
Net decrease in cash and cash equivalents	(6,826)
Cash and cash equivalents at beginning of the period	50,510
Cash and cash equivalents at end of the period	43,684
Effect of acquisitions:
Assets acquired, excluding cash	44,028
Liabilities assumed	(3,628)
Cash paid for acquisitions, net of cash acquired	$ 40,400

Description of Business and Basis of Presentation

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Description of Business and Basis of Presentation

1.	Description of Business and Basis of Presentation

Description of Business

Acadia Healthcare Company, Inc. (the “Company”) develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States (“U.S.”), the United Kingdom (“U.K.”) and Puerto Rico. At March 31, 2020, the Company operated 588 behavioral healthcare facilities with approximately 18,200 beds in 40 states, the U.K. and Puerto Rico.

During 2019, the Company commenced a review of strategic alternatives including those related to its U.K. operations and a potential sale of such operations. In January 2020, the Company launched a formal process regarding the sale of its U.K. business. Consistent with market practice for U.K. transactions of this nature, and in conjunction with its advisors, the Company solicited and has received initial, non-binding offers to acquire its U.K. business from multiple bidders. During the first quarter of 2020, the Company began the second phase of the sale process, during which interested bidders would receive proposed transaction documents and complete their confirmatory due diligence. While the interest from potential buyers has been strong, given evolving market dynamics related to the novel coronavirus (“COVID-19”) pandemic, the Company temporarily suspended the sale process in mid-March 2020 until market conditions recover.

Basis of Presentation

The business of the Company is conducted through limited liability companies, partnerships and C-corporations. The Company’s consolidated financial statements include the accounts of the Company and all subsidiaries controlled by the Company through its direct or indirect ownership of majority interests and exclusive rights granted to the Company as the controlling member of an entity. All intercompany accounts and transactions have been eliminated in consolidation.

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for fair presentation of our financial position and results of operations have been included. The Company’s fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited financial statements as of that date. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the fiscal year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 28, 2020. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

During March 2020, the global pandemic of COVID-19 began to affect the Company’s facilities, employees, patients, communities, business operations and financial performance, as well as the broader U.S. and U.K. economies and financial markets. At a limited number of facilities, employees and/or patients have tested positive for COVID-19. The Company is committed to protecting the health of our communities and has been responding to the evolving COVID-19 situation while taking steps to provide quality care and protect the health and safety of patients and employees. All of the Company’s facilities are closely following infectious disease protocols, as well as recommendations by the Centers for Disease Control and Prevention (“CDC”) and local health officials. The Company has established an internal COVID-19 taskforce, taken steps to secure its supply chain, expanded telehealth capabilities and implemented emergency planning in directly impacted markets. Nevertheless, COVID-19 is adversely impacting the Company’s business and likely will have an impact on its financial results that the Company is not currently able to quantify. Continued disruptions to the Company’s business as a result of the COVID-19 pandemic could have a material adverse effect on its results of operations, financial condition, cash flows and ability to service its indebtedness and may affect the amounts reported in the consolidated financial statements including those related to collectability of accounts receivable as well as professional and general liability reserves, tax assets and liabilities and may result in a potential impairment of goodwill and long-lived assets.

Certain reclassifications have been made to prior years to conform to the current year presentation.

Recently Issued Accounting Standards

3 Months Ended

Mar. 31, 2020

Accounting Changes And Error Corrections [Abstract]

Recently Issued Accounting Standards

2.	Recently Issued Accounting Standards

In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). ASU 2020-04 provides optional guidance for a limited period of time to ease the potential burden in accounting for or recognizing the effects of reference rate reform on financial reporting and applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 is effective as of March 12, 2020 through December 31, 2022. Entities may adopt ASU 2020-04 as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020 or prospectively from a date within an interim period that includes or is subsequent to March 12, 2020, up to the date that the financial statements are available to be issued. Management is evaluating the impact of ASU 2020-04 on the Company’s consolidated financial statements.

In August 2018, the FASB issued ASU 2018-15, “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (“ASU 2018-15”). ASU 2018-15 requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-402 to determine which implementation costs to capitalize as assets. ASU 2018-15 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. The Company adopted ASU 2018-15 on January 1, 2020. There is no significant impact on the Company’s consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). ASU 2016-13 replaces the current incurred loss impairment methodology with a new methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. The Company adopted ASU 2016-13 on January 1, 2020. There is no significant impact on the Company’s consolidated financial statements.

Revenue

3 Months Ended

Mar. 31, 2020

Revenue From Contract With Customer [Abstract]

Revenue

Revenue is primarily derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care and residential treatment. The services provided by the Company have no fixed duration and can be terminated by the patient or the facility at any time, and therefore, each treatment is its own stand-alone contract.

As our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in Accounting Standards Codification (“ASC”) ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance obligations at the end of the reporting period as our patients typically are under no obligation to remain admitted in our facilities.

The Company disaggregates revenue from contracts with customers by service type and by payor within each of the Company’s segments.

U.S. Facilities

The Company’s facilities in the United States (the “U.S. Facilities”) and services provided by the U.S. Facilities can generally be classified into the following categories: acute inpatient psychiatric facilities; specialty treatment facilities; residential treatment centers; and outpatient community-based facilities.

Acute inpatient psychiatric facilities. Acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. The acute setting provides 24-hour observation, daily intervention and monitoring by psychiatrists.

Specialty treatment facilities. Specialty treatment facilities include residential recovery facilities, eating disorder facilities and comprehensive treatment centers. The Company provides a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders. Inpatient, including detoxification and rehabilitation, partial hospitalization and outpatient treatment programs give patients access to the least restrictive level of care.

Residential treatment centers. Residential treatment centers treat patients with behavioral disorders in a non-hospital setting, including outdoor programs. The facilities balance therapy activities with social, academic and other activities.

Outpatient community-based facilities. Outpatient community-based programs are designed to provide therapeutic treatment to children and adolescents who have a clinically-defined emotional, psychiatric or chemical dependency disorder while enabling the youth to remain at home and within their community.

The table below presents total U.S. revenue attributed to each category (in thousands):

	Three Months Ended March 31,
	2020		2019
Acute inpatient psychiatric facilities	$	239,414	$	216,597
Specialty treatment facilities		193,611		193,035
Residential treatment centers		70,434		73,224
Outpatient community-based facilities		5,758		5,104
Revenue	$	509,217	$	487,960

The Company receives payments from the following sources for services rendered in our U.S. Facilities: (i) state governments under their respective Medicaid and other programs; (ii) commercial insurers; (iii) the federal government under the Medicare program administered by the Centers for Medicare and Medicaid Services (“CMS”); and (iv) individual patients and clients.

The Company determines the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and implicit price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. Implicit price concessions are based on historical collection experience. Most of our U.S. Facilities have contracts containing variable consideration. However, it is unlikely a significant reversal of revenue will occur when the uncertainty is resolved, and therefore, the Company has included the variable consideration in the estimated transaction price. Subsequent changes resulting from a patient’s ability to pay are recorded as bad debt expense, which is included as a component of other operating expenses in the condensed consolidating statements of income. Bad debt expense for the three months ended March 31, 2020 and 2019 was not significant.

The following table presents revenue by payor type and as a percentage of revenue in our U.S. Facilities (in thousands):

	Three Months Ended March 31,
	2020					2019
	Amount		%			Amount		%
Commercial	$	143,142		28.1	%	$	139,427		28.6	%
Medicare		72,271		14.2	%		72,616		14.9	%
Medicaid		260,044		51.1	%		239,191		49.0	%
Self-Pay		27,034		5.3	%		31,732		6.5	%
Other		6,726		1.3	%		4,994		1.0	%
Revenue	$	509,217		100.0	%	$	487,960		100.0	%

U.K. Facilities

The Company’s facilities located in the United Kingdom (the “U.K. Facilities”) and services provided by the U.K. Facilities can generally be classified into the following categories: healthcare facilities; education and children’s services; and adult care facilities.

Healthcare facilities. Healthcare facilities provide psychiatric treatment and nursing for sufferers of mental disorders, including for patients whose risk of harm to others and risk of escape from hospitals cannot be managed safely within other mental health settings. In order to manage the risks involved with treating patients, the facility is managed through the application of a range of security measures depending on the level of dependency and risk exhibited by the patient.

Education and children’s services. Education and children’s services provide specialist education for children and young people with special educational needs, including autism, Asperger’s Syndrome, social, emotional and mental health, and specific learning

difficulties, such as dyslexia. The division also offers standalone children’s homes for children that require 52-week residential care to support complex and challenging behavior and fostering services.

Adult care facilities. Adult care focuses on care of individuals with a variety of learning difficulties, mental health illnesses and adult autism spectrum disorders. It also includes long-term, short-term and respite nursing care to high-dependency elderly individuals who are physically frail or suffering from dementia. Care is provided in a number of settings, including in residential care homes and through supported living.

The table below presents total U.K. revenue attributed to each category (in thousands):

	Three Months Ended March 31,
	2020		2019
Healthcare facilities	$	148,137	$	151,708
Education and Children’s Services		46,666		46,122
Adult Care facilities		78,790		74,827
Revenue	$	273,593	$	272,657

On an annual basis, the Company receives payments from approximately 500 public funded sources in the U.K. (including the National Health Service (“NHS”), Clinical Commissioning Groups (“CCGs”) and local authorities in England, Scotland and Wales) and individual patients and clients. The Company determines the transaction price based on established billing rates by payor reduced by implicit price concessions. Implicit price concessions are insignificant in the U.K. Facilities.

The following table presents revenue by payor type and as a percentage of revenue in our U.K. Facilities (in thousands):

	Three Months Ended March 31,
	2020					2019
	Amount		%			Amount		%
U.K. public funded sources	$	246,136		90.0	%	$	245,413		90.0	%
Self-Pay		26,915		9.8	%		26,814		9.8	%
Other		542		0.2	%		430		0.2	%
Revenue	$	273,593		100.0	%	$	272,657		100.0	%

The Company’s contract liabilities primarily consist of unearned revenue in our U.K. Facilities due to the timing of payments received mainly in our education and children’s services and healthcare facilities. Contract liabilities are included in other accrued liabilities on the condensed consolidated balance sheets. A summary of the activity in unearned revenue in the U.K. Facilities is as follows (in thousands):

Balance at December 31, 2019	$	36,579
Payments received		38,152
Revenue recognized		(42,787	)
Foreign currency translation loss		(1,891	)
Balance at March 31, 2020	$	30,053

Earnings Per Share

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Earnings Per Share

4.	Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the three months ended March 31, 2020 and 2019 (in thousands, except per share amounts):

	Three Months Ended March 31,
	2020		2019
Numerator:
Net income attributable to Acadia Healthcare Company, Inc.	$	33,463	$	29,471
Denominator:
Weighted average shares outstanding for basic earnings per share		87,765		87,505
Effect of dilutive instruments		206		189
Shares used in computing diluted earnings per common share		87,971		87,694
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$	0.38	$	0.34
Diluted	$	0.38	$	0.34

Approximately 2.9 million and 2.6 million shares of common stock issuable upon exercise of outstanding stock option awards were excluded from the calculation of diluted earnings per share for the three months ended March 31, 2020 and 2019, respectively, because their effect would have been anti-dilutive.

Acquisitions

3 Months Ended

Mar. 31, 2020

Business Combinations [Abstract]

Acquisitions

5.	Acquisitions

The Company’s strategy is to acquire and develop behavioral healthcare facilities and improve operating results within its facilities and its other behavioral healthcare operations.

On April 1, 2019, the Company completed the acquisition of Bradford Recovery Center (“Bradford”), a specialty treatment facility with 46 beds located in Millerton, Pennsylvania, for cash consideration of approximately $4.5 million.

On February 15, 2019, the Company completed the acquisition of Whittier Pavilion (“Whittier”), an inpatient psychiatric facility with 71 beds located in Haverhill, Massachusetts, for cash consideration of approximately $17.9 million. Also on February 15, 2019, the Company completed the acquisition of Mission Treatment (“Mission Treatment”) for cash consideration of approximately $22.5 million. Mission Treatment operates nine comprehensive treatment centers in California, Nevada, Arizona and Oklahoma.

Transaction-related expenses

Transaction-related expenses primarily relate to termination, restructuring, U.K. sale, strategic review, management transition and other similar costs. Transaction-related expenses for the three months ended March 31, 2020 and 2019 were as follows (in thousands):

	Three Months Ended March 31,
	2020		2019
Termination, restructuring, sale and strategic review costs	$	2,221	$	2,282
Legal, accounting and other acquisition-related costs		1,328		796
Management transition costs		—		1,243
	$	3,549	$	4,321

Property and Equipment

3 Months Ended

Mar. 31, 2020

Property Plant And Equipment [Abstract]

Property and Equipment

6.	Property and Equipment

Property and equipment consisted of the following at March 31, 2020 and December 31, 2019 (in thousands):

	March 31, 2020			December 31, 2019
Land	$	429,601		$	448,716
Building and improvements		2,738,302			2,746,111
Equipment		502,246			516,769
Construction in progress		229,058			254,213
		3,899,207			3,965,809
Less: accumulated depreciation		(747,468	)		(741,775	)
Property and equipment, net	$	3,151,739		$	3,224,034

The Company has recorded assets held for sale within other assets on the condensed consolidated balance sheets for closed properties being actively marketed of $30.3 million and $31.1 million at March 31, 2020 and December 31, 2019, respectively.

Other Intangible Assets

3 Months Ended

Mar. 31, 2020

Goodwill And Intangible Assets Disclosure [Abstract]

Other Intangible Assets

7.	Other Intangible Assets

Other identifiable intangible assets and related accumulated amortization consisted of the following at March 31, 2020 and December 31, 2019 (in thousands):

	Gross Carrying Amount				Accumulated Amortization
	March 31, 2020		December 31, 2019		March 31, 2020			December 31, 2019
Intangible assets subject to amortization:
Contract intangible assets	$	2,100	$	2,100	$	(2,100	)	$	(2,100	)
Non-compete agreements		1,131		1,131		(1,131	)		(1,131	)
		3,231		3,231		(3,231	)		(3,231	)
Intangible assets not subject to amortization:
Licenses and accreditations		12,429		12,455		—			—
Trade names		59,532		60,831		—			—
Certificates of need		17,091		17,071		—			—
		89,052		90,357		—			—
Total	$	92,283	$	93,588	$	(3,231	)	$	(3,231	)

All of the Company’s definite-lived intangible assets are fully amortized. The Company’s licenses and accreditations, trade names and certificate of need intangible assets have indefinite lives and are, therefore, not subject to amortization.

Leases

3 Months Ended

Mar. 31, 2020

Leases [Abstract]

Leases

The Company’s lease portfolio primarily consists of finance and operating real estate leases integral for facility operations. The original terms of the leases typically range from five to 30 years with optional renewal periods. A minimal portion of the Company’s lease portfolio consists of non-real estate leases, including copiers and equipment, which generally have lease terms of one to three years and have insignificant lease obligations.

The Company has elected the accounting policy practical expedients by class of underlying asset in ASC 842 “Leases” to: (i) combine associated lease and non-lease components into a single lease component; and (ii) exclude recording short-term leases as right-of-use assets and liabilities on the condensed consolidated balance sheets. Non-lease components, which are not significant overall, are combined with lease components.

Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for prepayments, accrued lease payments, lease incentives and initial direct costs. Certain of the Company’s leases include renewal or termination options. Calculation of operating lease right-of-use assets and liabilities include the initial lease term unless it is reasonably certain a renewal or termination option will be exercised. Variable components of lease payments fluctuating with a future index or rate, as well as those related to common area maintenance costs, are not included in determining lease payments and are expensed as incurred. Most of the Company’s leases do not contain implicit borrowing rates, and therefore,

incremental borrowing rates are calculated based on information available at the lease commencement date. Incremental borrowing rates reflect the Company’s estimated interest rates for collateralized borrowings over similar lease terms. Additionally, the Company reviews service agreements for embedded lease and right-of-use assets and liabilities as necessary.

Lease Position

The Company recorded the following at March 31, 2020 and December 31, 2019 on the condensed consolidated balance sheets (in thousands):

Right-of-Use Assets	Balance Sheet Classification	March 31, 2020		December 31, 2019
Finance lease right-of-use assets	Property and equipment, net	$	43,760	$	44,370
Operating lease right-of-use assets	Operating lease right-of-use assets		476,028		501,837
Total		$	519,788	$	546,207

Lease Liabilities	Balance Sheet Classification	March 31, 2020		December 31, 2019
Current:
Finance lease liabilities	Other accrued liabilities	$	6,637	$	6,819
Operating lease liabilities	Current portion of operating lease liabilities		29,671		29,140
Noncurrent:
Finance lease liabilities	Other liabilities		43,295		43,662
Operating lease liabilities	Operating lease liabilities		474,746		502,252
Total		$	554,349	$	581,873

Weighted-average remaining lease terms and discount rates were as follows at March 31, 2020 and December 31, 2019:

	March 31, 2020			December 31, 2019
Weighted-average remaining lease term (in years):
Finance	6.7			6.9
Operating		19.0		19.4

Weighted-average discount rate:
Finance		6.4	%		6.4	%
Operating		6.3	%		6.3	%

Lease Costs

The Company recorded the following lease costs for the three months ended March 31, 2020 and 2019 (in thousands):

	Three Months Ended March 31,
	2020		2019
Finance lease costs:
Depreciation of leased assets		1,137		1,123
Interest of lease liabilities		997		997
Total finance lease costs	$	2,134	$	2,120

Operating lease costs		16,481		16,529
Variable lease costs		1,310		886
Short term lease costs		1,147		1,447
Other lease costs		1,886		1,445
Total rents and leases	$	20,824	$	20,307

Total lease costs	$	22,958	$	22,427

Other

Undiscounted cash flows for finance and operating leases recorded on the condensed consolidated balance sheets were as follows at March 31, 2020 (in thousands):

	Finance Leases		Operating Leases
For the nine months ending December 31, 2020	$	5,549	$	45,846
2021		35,726		58,023
2022		2,845		52,956
2023		1,620		48,544
2024		1,027		46,312
Thereafter		25,088		650,931
Total minimum lease payments		71,855		902,612
Less: amount of lease payments representing interest		21,923		398,195
Present value of future minimum lease payments		49,932		504,417
Less: Current portion of lease liabilities		6,637		29,671
Noncurrent lease liabilities	$	43,295	$	474,746

Supplemental data for the three months ended March 31, 2020 and 2019 was as follows (in thousands):

	Three Months Ended March 31,
	2020		2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	15,836	$	15,809
Operating cash flows for finance leases	$	997	$	997
Financing cash flows for finance leases	$	878	$	846

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	6,082	$	3,662
Finance leases	$	953	$	1,027

Long-Term Debt

3 Months Ended

Mar. 31, 2020

Debt Disclosure [Abstract]

Long-Term Debt

9.Long-Term Debt

Long-term debt consisted of the following (in thousands):

	March 31, 2020			December 31, 2019
Amended and Restated Senior Credit Facility:
Senior Secured Term A Loan	$	339,625		$	346,750
Senior Secured Term B Loans		1,335,432			1,338,928
Senior Secured Revolving Line of Credit		—			—
6.125% Senior Notes due 2021		150,000			150,000
5.125% Senior Notes due 2022		300,000			300,000
5.625% Senior Notes due 2023		650,000			650,000
6.500% Senior Notes due 2024		390,000			390,000
Other long-term debt		4,533			4,821
Less: unamortized debt issuance costs, discount and premium		(28,698	)		(31,400	)
		3,140,892			3,149,099
Less: current portion		(196,072	)		(43,679	)
Long-term debt	$	2,944,820		$	3,105,420

Amended and Restated Senior Credit Facility

The Company entered into a senior secured credit facility (the “Senior Secured Credit Facility”) on April 1, 2011. On December 31, 2012, the Company entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) which amended and restated the Senior Secured Credit Facility (the “Amended and Restated Senior Credit Facility”). The Company has amended the Amended and Restated Credit Agreement from time to time as described in the Company’s prior filings with the SEC.

On February 6, 2019, the Company entered into the Eleventh Amendment (the “Eleventh Amendment”) to the Amended and Restated Credit Agreement. The Eleventh Amendment, among other things, amended the definition of “Consolidated EBITDA” to remove the cap on non-cash charges, losses and expenses related to the impairment of goodwill, which in turn provided increased flexibility to the Company in terms of the Company’s financial covenants.

On February 27, 2019, the Company entered into the Twelfth Amendment (the “Twelfth Amendment”) to the Amended and Restated Credit Agreement. The Twelfth Amendment, among other things, modified certain definitions, including “Consolidated EBITDA”, and increased our permitted Maximum Consolidated Leverage Ratio, thereby providing increased flexibility to the Company in terms of the Company’s financial covenants.

On April 21, 2020, the Company entered into the Thirteenth Amendment (the “Thirteenth Amendment”) to the Amended and Restated Credit Agreement. The Thirteenth Amendment amended the Consolidated Leverage Ratio in the existing covenant to increase the leverage ratio for the rest of 2020.

The Company had $485.0 million of availability under the revolving line of credit and had standby letters of credit outstanding of $15.0 million related to security for the payment of claims required by its workers’ compensation insurance program at March 31, 2020. In early April 2020, the Company borrowed $100.0 million on the revolving line of credit to enhance its cash position in response to the potential impact of COVID-19 on the Company’s future liquidity. Borrowings under the revolving line of credit are subject to customary conditions precedent to borrowing.

The Amended and Restated Credit Agreement requires quarterly term loan principal repayments of our Term Loan A facility (“TLA Facility”) of $7.1 million for June 30, 2020 to December 31, 2020, and $9.5 million for March 31, 2021 to September 30, 2021, with the remaining principal balance of the TLA Facility due on the maturity date of November 30, 2021. The Company is required to repay the Term Loan B facility Tranche B-3 (the “Tranche B-3 Facility”) in equal quarterly installments of $1.2 million on the last business day of each March, June, September and December, with the outstanding principal balance of the Tranche B-3 Facility of $447.3 million due on February 11, 2022. The Company is required to repay the Term Loan B facility Tranche B-4 (the “Tranche B-4 Facility”) in equal quarterly installments of approximately $2.3 million on the last business day of each March, June, September and December, with the outstanding principal balance of the Tranche B-4 Facility of $854.4 million due on February 16, 2023.

Borrowings under the Amended and Restated Senior Credit Facility are guaranteed by each of the Company’s wholly-owned domestic subsidiaries (other than certain excluded subsidiaries) and are secured by a lien on substantially all of the assets of the Company and such subsidiaries. Borrowings with respect to the TLA Facility and the Company’s revolving credit facility (collectively, “Pro Rata Facilities”) under the Amended and Restated Credit Agreement bear interest at a rate tied to Acadia’s Consolidated Leverage Ratio (defined as consolidated funded debt net of up to $50.0 million of unrestricted and unencumbered cash to consolidated EBITDA, in each case as defined in the Amended and Restated Credit Agreement). The Applicable Rate (as defined in the Amended and Restated Credit Agreement) for the Pro Rata Facilities was 2.50% for Eurodollar Rate Loans (as defined in the Amended and Restated Credit Agreement) and 1.50% for Base Rate Loans (as defined in the Amended and Restated Credit Agreement) at March 31, 2020. Eurodollar Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the Eurodollar Rate (as defined in the Amended and Restated Credit Agreement) (based upon the LIBOR Rate (as defined in the Amended and Restated Credit Agreement) prior to commencement of the interest rate period). Base Rate Loans with respect to the Pro Rata Facilities bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.00%. At March 31, 2020, the Pro Rata Facilities bore interest at a rate of LIBOR plus 2.50%. In addition, the Company is required to pay a commitment fee on undrawn amounts under the revolving line of credit.

Eurodollar Rate Loans with respect to the Tranche B-3 Facility bear interest at the Tranche B-3 Facility Applicable Rate (as defined below) plus the Eurodollar Rate (subject to a floor of 0.75% and based upon the LIBOR Rate prior to commencement of the interest rate period). Base Rate Loans bear interest at the Tranche B-3 Facility Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As used herein, the term “Tranche B-3 Facility Applicable Rate” means, with respect to Eurodollar Rate Loans, 2.50%, and with respect to Base Rate Loans, 1.50%. The Tranche B-4 Facility bears interest as follows: Eurodollar Rate Loans bear interest at the Applicable Rate (as defined in the Amended and Restated Credit Agreement) plus the Eurodollar Rate (subject to a floor of 0.75% and based upon the LIBOR Rate prior to commencement of the

interest rate period) and Base Rate Loans bear interest at the Applicable Rate plus the highest of (i) the federal funds rate plus 0.50%, (ii) the prime rate and (iii) the Eurodollar Rate plus 1.0%. As used herein, the term “Applicable Rate” means, with respect to Eurodollar Rate Loans, 2.50%, and with respect to Base Rate Loans, 1.50%.

The Amended and Restated Credit Agreement requires the Company and its subsidiaries to comply with customary affirmative, negative and financial covenants, including a fixed charge coverage ratio, consolidated leverage ratio and senior secured leverage ratio. The Company may be required to pay all of its indebtedness immediately if it defaults on any of the numerous financial or other restrictive covenants contained in any of its material debt agreements. At March 31, 2020, the Company was in compliance with such covenants.

Senior Notes

6.125% Senior Notes due 2021

On March 12, 2013, the Company issued $150.0 million of 6.125% Senior Notes due 2021 (the “6.125% Senior Notes”). The 6.125% Senior Notes mature on March 15, 2021 and bear interest at a rate of 6.125% per annum, payable semi-annually in arrears on March 15 and September 15 of each year. At March 31, 2020, the 6.125% Senior Notes are included in current portion of debt on the condensed consolidated balance sheet.

5.125% Senior Notes due 2022

On July 1, 2014, the Company issued $300.0 million of 5.125% Senior Notes due 2022 (the “5.125% Senior Notes”). The 5.125% Senior Notes mature on July 1, 2022 and bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on January 1 and July 1 of each year.

5.625% Senior Notes due 2023

On February 11, 2015, the Company issued $375.0 million of 5.625% Senior Notes due 2023 (the “5.625% Senior Notes”). On September 21, 2015, the Company issued $275.0 million of additional 5.625% Senior Notes. The additional notes formed a single class of debt securities with the 5.625% Senior Notes issued in February 2015. Giving effect to this issuance, the Company has outstanding an aggregate of $650.0 million of 5.625% Senior Notes. The 5.625% Senior Notes mature on February 15, 2023 and bear interest at a rate of 5.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year.

6.500% Senior Notes due 2024

On February 16, 2016, the Company issued $390.0 million of 6.500% Senior Notes due 2024 (the “6.500% Senior Notes”). The 6.500% Senior Notes mature on March 1, 2024 and bear interest at a rate of 6.500% per annum, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016.

The indentures governing the 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes and 6.500% Senior Notes (together, the “Senior Notes”) contain covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries to: (i) pay dividends, redeem stock or make other distributions or investments; (ii) incur additional debt or issue certain preferred stock; (iii) transfer or sell assets; (iv) engage in certain transactions with affiliates; (v) create restrictions on dividends or other payments by the restricted subsidiaries; (vi) merge, consolidate or sell substantially all of the Company’s assets; and (vii) create liens on assets.

The Senior Notes issued by the Company are guaranteed by each of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. The guarantees are full and unconditional and joint and several.

The Company may redeem the Senior Notes at its option, in whole or part, at the dates and amounts set forth in the indentures.

Equity-Based Compensation

3 Months Ended

Mar. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity-Based Compensation

10.	Equity-Based Compensation

Equity Incentive Plans

The Company issues stock-based awards, including stock options, restricted stock and restricted stock units, to certain officers, employees and non-employee directors under the Acadia Healthcare Company, Inc. Incentive Compensation Plan (the “Equity Incentive Plan”). At March 31, 2020, a maximum of 8,200,000 shares of the Company’s common stock were authorized for issuance as stock options, restricted stock and restricted stock units or other share-based compensation under the Equity Incentive Plan, of

which 1,024,052 were available for future grant. Stock options may be granted for terms of up to ten years. The Company recognizes expense on all share-based awards on a straight-line basis over the requisite service period of the entire award. Grants to employees generally vest in annual increments of 25% each year, commencing one year after the date of grant. The exercise prices of stock options are equal to the most recent closing price of the Company’s common stock on the most recent trading date prior to the date of grant.

The Company recognized $5.0 million and $6.1 million in equity-based compensation expense for the three months ended March 31, 2020 and 2019, respectively. At March 31, 2020, there was $50.8 million of unrecognized compensation expense related to unvested options, restricted stock and restricted stock units, which is expected to be recognized over the remaining weighted average vesting period of 1.5 years.

At March 31, 2020, there were no warrants outstanding and exercisable. The Company recognized a deferred income tax benefit of $1.3 million and $1.6 million for the three months ended March 31, 2020 and 2019, respectively, related to equity-based compensation expense.

Stock Options

Stock option activity during 2019 and 2020 was as follows (aggregate intrinsic value in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2019		1,199,540		$	44.64		7.26	$	2,717
Options granted		605,200			28.50		9.21		1,343
Options exercised		(55,671	)		19.05	N/A			658
Options cancelled		(389,001	)		40.84	N/A		N/A
Options outstanding at December 31, 2019		1,360,068			39.40		7.57		1,650
Options granted		443,200			33.72		9.91		—
Options exercised		—			—	N/A			—
Options cancelled		(105,462	)		41.00	N/A		N/A
Options outstanding at March 31, 2020		1,697,806		$	37.81		7.97	$	659
Options exercisable at December 31, 2019		513,290		$	48.08		5.88	$	512
Options exercisable at March 31, 2020		702,956		$	44.08		6.36	$	479

Fair values are estimated using the Black-Scholes option pricing model. The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the three months ended March 31, 2020 and year ended December 31, 2019:

	March 31, 2020			December 31, 2019
Weighted average grant-date fair value of options	$	12.29		$	17.59
Risk-free interest rate		1.6	%		2.4	%
Expected volatility		39	%		38	%
Expected life (in years)		5.0			5.0

The Company’s estimate of expected volatility for stock options is based upon the volatility of our stock price over the expected life of the award. The risk-free interest rate is the approximate yield on U.S. Treasury Strips having a life equal to the expected option life on the date of grant. The expected life is an estimate of the number of years an option will be held before it is exercised.

Other Stock-Based Awards

Restricted stock activity during 2019 and 2020 was as follows:

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2019		805,057		$	42.40
Granted		700,937			28.77
Cancelled		(389,684	)		33.50
Vested		(311,174	)		44.23
Unvested at December 31, 2019		805,136		$	34.14
Granted		511,006			25.37
Cancelled		(57,782	)		35.55
Vested		(160,398	)		36.73
Unvested at March 31, 2020		1,097,962		$	29.61

Restricted stock unit activity during 2019 and 2020 was as follows:

	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2019		484,111		$	44.52
Granted		234,408			34.54
Cancelled		(271,162	)		45.17
Vested		—			—
Unvested at December 31, 2019		447,357		$	38.89
Granted		583,680			10.60
Cancelled		(10,123	)		42.09
Vested		(12,691	)		42.09
Unvested at March 31, 2020		1,008,223		$	22.44

Restricted stock awards are time-based vesting awards that vest over a period of three or four years and are subject to continuing service of the employee or non-employee director over the ratable vesting periods. The fair values of the restricted stock awards were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date.

Restricted stock units are granted to employees and are subject to Company performance compared to pre-established targets and Company performance compared to peers. In addition to Company performance, these performance-based restricted stock units are subject to the continuing service of the employee during the two- or three-year period covered by the awards. The performance condition for the restricted stock units is based on the Company’s achievement of annually established targets for diluted earnings per share. Additionally, the number of shares issuable pursuant to restricted stock units granted during 2020 and 2019 are subject to adjustment based on the Company’s three-year annualized total stockholder return relative to a peer group consisting of S&P 1500 companies within the Healthcare Providers & Services 6 digit GICS industry group and selected other companies deemed to be peers. The number of shares issuable at the end of the applicable vesting period of restricted stock units ranges from 0% to 200% of the targeted units based on the Company’s actual performance compared to the targets and, for 2020 and 2019 awards, performance compared to peers.

The fair values of restricted stock units were determined based on the closing price of the Company’s common stock on the trading date immediately prior to the grant date for units subject to performance conditions, or at its Monte-Carlo simulation value for units subject to market conditions.

Income Taxes

3 Months Ended

Mar. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes

11.	Income Taxes

The provision for income taxes for the three months ended March 31, 2020 and 2019 reflects effective tax rates of 14.5% and 20.0%, respectively. The decrease in the effective tax rate for the three months ended March 31, 2020 was primarily attributable to the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”). The Company recorded a discrete benefit during the three

months ended March 31, 2020 resulting from a change in the Company’s valuation allowance related to a decrease in the deferred tax asset on carried forward interest.

As we continue to monitor tax implications of the CARES Act and other state, federal and foreign stimulus and tax legislation, we may make adjustments to our estimates and record additional amounts for tax assets and liabilities. Additionally, market disruption due to COVID-19 may affect the Company’s ability to realize our deferred tax assets. Any adjustments to our tax assets and liabilities could materially impact our provision for income taxes and our effective tax rate in the periods in which they are made.

Derivatives

3 Months Ended

Mar. 31, 2020

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Derivatives

12.	Derivatives

The Company periodically enters into foreign currency forward contracts in connection with certain transfers of cash between the U.S. and U.K. under the Company’s cash management and foreign currency risk management programs. Foreign currency forward contracts limit the economic risk of changes in the exchange rate between U.S. Dollars (“USD”) and British Pounds (“GBP”) associated with cash transfers.

In May 2016, the Company entered into multiple cross currency swap agreements with an aggregate notional amount of $650.0 million to manage foreign currency risk by effectively converting a portion of its fixed-rate USD-denominated senior notes, including the semi-annual interest payments thereafter, to fixed-rate GBP-denominated debt of £449.3 million. In August 2019, the Company terminated its existing net investment cross currency swap derivatives of $105.0 million. Cash received from the termination of the cross currency swap derivatives was included in investing activities in the condensed consolidated statement of cash flows. The related gain from this termination was included in accumulated other comprehensive loss in accordance with ASC 815-30-40-1.

In August 2019, the Company also entered into multiple cross currency swap agreements with an aggregate notional amount of $650.0 million to manage foreign currency risk by effectively converting a portion of its fixed-rate USD-denominated senior notes, including the semi-annual interest payments thereunder, to fixed-rate GBP-denominated debt of £538.1 million. During the term of the swap agreements, the Company will receive semi-annual interest payments in USD from the counterparties at fixed interest rates, and the Company will make semi-annual interest payments in GBP to the counterparties at fixed interest rates. The interest payments under the cross-currency swap agreements result in £25.4 million of annual cash flows from the Company’s U.K. business being converted to $35.8 million.

The Company has designated the cross currency swap agreements and forward contracts entered into during 2019 and the three months ended March 31, 2020 as qualifying hedging instruments and is accounting for these derivatives as net investment hedges. The fair values of these derivatives at March 31, 2020 and December 31, 2019 of $(9.0) million and $(68.9) million, respectively, are recorded as derivative instrument liabilities on the condensed consolidated balance sheets. During the three months ended March 31, 2020, the Company elected the spot method for recording its net investment hedges. Gains and losses resulting from the settlement of the excluded components are recorded in interest expense on the condensed consolidated statements of income. Gains and losses resulting from fair value adjustments to the cross currency swap agreements are recorded in accumulated other comprehensive loss as the swaps are effective in hedging the designated risk. Cash flows related to the cross currency swap derivatives are included in operating activities in the condensed consolidated statements of cash flows.

Fair Value Measurements

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

13.	Fair Value Measurements

The carrying amounts reported for cash and cash equivalents, accounts receivable, other current assets, accounts payable and other current liabilities approximate fair value because of the short-term maturity of these instruments.

The carrying amounts and fair values of the Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes, other long-term debt and derivative instruments at March 31, 2020 and December 31, 2019 were as follows (in thousands):

	Carrying Amount						Fair Value
	March 31, 2020			December 31, 2019			March 31, 2020			December 31, 2019
Amended and Restated Senior Credit Facility	$	1,659,098		$	1,668,062		$	1,659,098		$	1,668,062
6.125% Senior Notes due 2021	$	149,409		$	149,254		$	144,927		$	149,441
5.125% Senior Notes due 2022	$	297,973		$	297,761		$	283,998		$	299,994
5.625% Senior Notes due 2023	$	645,156		$	644,771		$	607,995		$	655,249
6.500% Senior Notes due 2024	$	384,723		$	384,430		$	374,143		$	398,366
Other long-term debt	$	4,533		$	4,821		$	4,533		$	4,821
Derivative instrument liabilities	$	(9,015	)	$	(68,915	)	$	(9,015	)	$	(68,915	)

The Company’s Amended and Restated Senior Credit Facility, 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes, 6.500% Senior Notes and other long-term debt were categorized as Level 2 in the GAAP fair value hierarchy. Fair values were based on trading activity among the Company’s lenders and the average bid and ask price as determined using published rates.

The fair values of the derivative instruments were categorized as Level 2 in the GAAP fair value hierarchy and were based on observable market inputs including applicable exchange rates and interest rates.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Commitments and Contingencies

3 Months Ended

Mar. 31, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

14.	Commitments and Contingencies

Professional and General Liability

A portion of the Company’s professional liability risks are insured through a wholly-owned insurance subsidiary. The Company is self-insured for professional liability claims up to $3.0 million per claim and has obtained reinsurance coverage from a third party to cover claims in excess of the retention limit. The reinsurance policy has a coverage limit of $75.0 million in the aggregate. The Company’s reinsurance receivables are recognized consistent with the related liabilities and include known claims and any incurred but not reported claims that are covered by current insurance policies in place.

Legal Proceedings

The Company is, from time to time, subject to various claims, lawsuits, governmental investigations and regulatory actions, including claims for damages for personal injuries, medical malpractice, overpayments, breach of contract, securities law violations, tort and employment related claims. In these actions, plaintiffs request a variety of damages, including, in some instances, punitive and other types of damages that may not be covered by insurance. In addition, healthcare companies are subject to numerous investigations by various governmental agencies. Certain of the Company’s individual facilities have received, and from time to time, other facilities may receive, subpoenas, civil investigative demands, audit requests and other inquiries from, and may be subject to investigation by, federal and state agencies. These investigations can result in repayment obligations, and violations of the False Claims Act can result in substantial monetary penalties and fines, the imposition of a corporate integrity agreement and exclusion from participation in governmental health programs. In addition, the federal False Claims Act permits private parties to bring qui tam, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions.

On April 1, 2019, a consolidated complaint was filed against the Company and certain former and current officers in the lawsuit styled St. Clair County Employees’ Retirement System v. Acadia Healthcare Company, Inc., et al., Case No. 3:19-cv-00988, which is pending in the United States District Court for the Middle District of Tennessee. The complaint purports to be brought on behalf of a class consisting of all persons (other than defendants) who purchased securities of the Company between April 30, 2014 and November 15, 2018, and alleges that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder. At this time, we are not able to quantify any potential liability in connection with this litigation because the case is in its early stages.

On February 21, 2019, a purported stockholder filed a related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled Davydov v. Joey A. Jacobs, et al., Case No. 3:19-cv-00167, which is pending in the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Section 10(b) and 14(a) of the Exchange Act, breach of fiduciary duty, waste of corporate assets, and unjust enrichment. On May 23, 2019, a purported stockholder filed a second related derivative action on behalf of the Company against certain former and current officers and directors in the lawsuit styled Beard v. Jacobs, et al., Case No. 3:19-cv-0441, which is pending the United States District Court for the Middle District of Tennessee. The complaint alleges claims for violations of Sections 10(b), 14(a), and 21D of the Exchange Act, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and insider selling. On June 11, 2019, the Davydov and Beard actions were consolidated and ordered stayed pending a ruling on the motion to dismiss that was filed in the St. Clair County v. Acadia Healthcare case described above. At this time, we are not able to quantify any potential liability in connection with this litigation because the cases are in their early stages.

On April 25, 2018, plaintiff filed Pence v. Sober Living By the Sea, Inc. - 30-2018-00988742-CU-OE-CXC, Orange County Superior Court (Pence I). On July 13, 2018, plaintiff next filed Pence v. Sober Living by the Sea, Inc.; Acadia Healthcare Company, Inc. - 30-2018-01005317-CU-OE-CJC, Orange County Superior Court (Pence II). These cases have now been consolidated before the same judge in the Complex Litigation Department of the Orange County Superior Court. The complaints allege various wage and hour violations under California law on behalf of a putative class of all non-exempt California employees of Acadia and various subsidiaries, going back to April 25, 2014, and on behalf of purportedly aggrieved non-exempt employees under California’s Private Attorney General Act (“PAGA”). The claims include (1) failure to provide overtime wages; (2); failure to provide minimum wages;

(3) failure to provide meal periods; (4) failure to provide rest periods; (5); failure to pay wages due at termination; (6) failure to provide accurate wage statements; (7) violations of California Business and Professions Code section 17200; and (8) civil penalties under California Labor Code section 2699 (PAGA). At this time, we are unable to quantify any potential liability in connection with this litigation because the cases are in their early stages.

In the fall of 2017, the Office of Inspector General issued subpoenas to three of the Company’s facilities requesting certain documents from January 2013 to the date of the subpoenas. The U.S. Attorney’s Office for the Middle District of Florida issued a civil investigative demand to one of the Company’s facilities in December 2017 requesting certain documents from November 2012 to the date of the demand. In April 2019, the Office of Inspector General issued subpoenas relating to six additional facilities requesting certain documents and information from January 2013 to the date of the subpoenas. The government’s investigation of each of these facilities is focused on claims not eligible for payment because of alleged violations of certain regulatory requirements relating to, among other things, medical necessity, admission eligibility, discharge decisions, length of stay and patient care issues. The Company is cooperating with the government’s investigation but is not able to quantify any potential liability in connection with these investigations.

Noncontrolling Interests

3 Months Ended

Mar. 31, 2020

Noncontrolling Interest [Abstract]

Noncontrolling Interests

15.	Noncontrolling Interests

Noncontrolling interests in the consolidated financial statements represents the portion of equity held by noncontrolling partners in the Company’s non-wholly owned subsidiaries. At March 31, 2020, the Company operated five facilities through non-wholly owned subsidiaries and owns between 60% and 86% of the equity interests, and noncontrolling partners own the remaining equity interests. The initial value of the noncontrolling interests is based on the fair value of contributions, and the Company consolidates the operations of each facility based on its equity ownership and its control of the entity. The noncontrolling interests are reflected as redeemable noncontrolling interests on the accompanying condensed consolidated balance sheets based on put rights that could require the Company to purchase the noncontrolling interests upon the occurrence of a change in control.

The components of redeemable noncontrolling interests are as follows (in thousands):

Balance at December 31, 2019	$	33,151
Net income attributable to noncontrolling interests		604
Dividend payments to noncontrolling interests		(264	)
Balance at March 31, 2020	$	33,491

Other Current Assets

3 Months Ended

Mar. 31, 2020

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Other Current Assets

16.	Other Current Assets

Other current assets consisted of the following (in thousands):

	March 31, 2020		December 31, 2019
Prepaid expenses	$	22,161	$	23,708
Cost report receivable		14,402		13,723
Other receivables		14,257		16,097
Workers’ compensation deposits – current portion		10,000		10,000
Income taxes receivable		9,358		5,579
Insurance receivable – current portion		5,739		3,030
Inventory		4,882		4,759
Other		1,644		1,348
Other current assets	$	82,443	$	78,244

Other Accrued Liabilities

3 Months Ended

Mar. 31, 2020

Other Liabilities Disclosure [Abstract]

Other Accrued Liabilities

17.	Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	March 31, 2020		December 31, 2019
Accrued expenses	$	41,131	$	50,614
Unearned income		31,631		38,475
Accrued interest		11,660		33,323
Finance lease liabilities		6,637		6,819
Insurance liability – current portion		4,731		4,731
Accrued property taxes		4,222		4,755
Other		4,346		2,443
Other accrued liabilities	$	104,358	$	141,160

Segment Information

3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Segment Information

18.	Segment Information

The Company operates in one line of business, which is operating acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and facilities providing outpatient behavioral healthcare services. As management reviews the operating results of its U.S. Facilities and its U.K. Facilities separately to assess performance and make decisions, the Company’s operating segments include our U.S. Facilities and U.K. Facilities. At March 31, 2020, the U.S. Facilities segment included 228 behavioral healthcare facilities with approximately 9,600 beds in 40 states and Puerto Rico, and the U.K. Facilities segment included 360 behavioral healthcare facilities with approximately 8,700 beds in the U.K.

The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income before income taxes (in thousands):

	Three Months Ended March 31,
	2020			2019
Revenue:
U.S. Facilities	$	509,217		$	487,960
U.K. Facilities		273,593			272,657
Corporate and Other		—			—
	$	782,810		$	760,617
Segment EBITDA (1):
U.S. Facilities	$	120,074		$	119,008
U.K. Facilities		36,168			40,056
Corporate and Other		(23,393	)		(23,061	)
	$	132,849		$	136,003

	Three Months Ended March 31,
	2020			2019
Segment EBITDA (1)	$	132,849		$	136,003
Less:
Equity-based compensation expense		(4,979	)		(6,101	)
Transaction-related expenses		(3,549	)		(4,321	)
Interest expense, net		(42,785	)		(48,130	)
Depreciation and amortization		(41,680	)		(40,580	)
Income before income taxes	$	39,856		$	36,871

	U.S. Facilities			U.K. Facilities			Corporate and Other		Consolidated
Goodwill:
Balance at January 1, 2020
Goodwill	$	2,085,104		$	689,902		$	—	$	2,775,006
Accumulated impairment loss		—			(325,875	)		—		(325,875	)
Net goodwill at January 1, 2020		2,085,104			364,027			—		2,449,131
Prior period purchase price adjustments		(13	)		—			—		(13	)
Foreign currency translation gain		—			(22,418	)		—		(22,418	)
Balance at March 31, 2020
Goodwill		2,085,091			667,484			—		2,752,575
Accumulated impairment loss		—			(325,875	)		—		(325,875	)
Net goodwill at March 31, 2020	$	2,085,091		$	341,609		$	—	$	2,426,700

	March 31, 2020		December 31, 2019
Assets (2):
U.S. Facilities	$	4,083,825	$	4,037,968
U.K. Facilities		2,443,498		2,610,357
Corporate and Other		190,672		230,817
	$	6,717,995	$	6,879,142

(1)

Segment EBITDA is defined as income before provision for income taxes, equity-based compensation expense, transaction-related expenses, interest expense and depreciation and amortization. The Company uses Segment EBITDA as an analytical indicator to measure the performance of the Company’s segments and to develop strategic objectives and operating plans for those segments. Segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Segment EBITDA should not be considered as a measure of financial performance under GAAP, and the items excluded from Segment EBITDA are significant components in understanding and assessing financial performance. Because Segment EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.

(2)

Assets include property and equipment for the U.S. Facilities of $1.5 billion, U.K. Facilities of $1.6 billion and corporate and other of $57.3 million at March 31, 2020. Assets include property and equipment for the U.S. Facilities of $1.4 billion, U.K. Facilities of $1.7 billion and corporate and other of $50.9 million at December 31, 2019.

Accumulated Other Comprehensive Loss

3 Months Ended

Mar. 31, 2020

Equity [Abstract]

Accumulated Other Comprehensive Loss

19.	Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

	Foreign Currency Translation Adjustments			Change in Fair Value of Derivative Instruments		Pension Plan			Total
Balance at December 31, 2019	$	(434,633	)	$	24,958	$	(5,209	)	$	(414,884	)
Foreign currency translation (loss) gain		(122,321	)		—		321			(122,000	)
Gain on derivative instruments, net of tax of $16.3 million		—			43,746		—			43,746
Balance at March 31, 2020	$	(556,954	)	$	68,704	$	(4,888	)	$	(493,138	)

Financial Information for the Company and Its Subsidiaries

3 Months Ended

Mar. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Financial Information for the Company and Its Subsidiaries

20.	Financial Information for the Company and Its Subsidiaries

The Company conducts substantially all of its business through its subsidiaries. The 6.125% Senior Notes, 5.125% Senior Notes, 5.625% Senior Notes and 6.500% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by all of the Company’s subsidiaries that guarantee the Company’s obligations under the Amended and Restated Senior Credit Facility. Presented below is condensed consolidating financial information for the Company and its subsidiaries at March 31, 2020 and December 31, 2019, and for the three months ended March 31, 2020 and 2019. The information segregates the parent company (Acadia Healthcare Company, Inc.), the combined wholly-owned subsidiary guarantors, the combined non-guarantor subsidiaries and eliminations.

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

March 31, 2020

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	51,340	$	29,664	$	—		$	81,004
Accounts receivable, net		—		272,098		67,407		—			339,505
Other current assets		—		65,346		17,097		—			82,443
Total current assets		—		388,784		114,168		—			502,952
Property and equipment, net		—		1,348,045		1,803,694		—			3,151,739
Goodwill		—		1,992,332		434,368		—			2,426,700
Intangible assets, net		—		58,312		30,740		—			89,052
Deferred tax assets		1,303		—		3,307		(1,303	)		3,307
Investment in subsidiaries		5,390,417		—		—		(5,390,417	)		—
Operating lease right-of-use assets		—		98,166		377,862		—			476,028
Other assets		234,014		48,597		12,214		(226,608	)		68,217
Total assets	$	5,625,734	$	3,934,236	$	2,776,353	$	(5,618,328	)	$	6,717,995

Current liabilities:
Current portion of long-term debt	$	196,072	$	—	$	—	$	—		$	196,072
Accounts payable		—		97,196		37,497		—			134,693
Accrued salaries and benefits		—		82,072		32,718		—			114,790
Current portion of operating lease liabilities		—		18,571		11,100		—			29,671
Other accrued liabilities		11,660		26,021		66,677		—			104,358
Total current liabilities		207,732		223,860		147,992		—			579,584
Long-term debt		2,944,820		—		226,608		(226,608	)		2,944,820
Deferred tax liabilities		—		41,087		45,621		(1,303	)		85,405
Operating lease liabilities		—		85,577		389,169		—			474,746
Derivative instrument liabilities		9,015		—		—		—			9,015
Other liabilities		—		110,923		15,844		—			126,767
Total liabilities		3,161,567		461,447		825,234		(227,911	)		4,220,337
Redeemable noncontrolling interests		—		—		33,491		—			33,491
Total equity		2,464,167		3,472,789		1,917,628		(5,390,417	)		2,464,167
Total liabilities and equity	$	5,625,734	$	3,934,236	$	2,776,353	$	(5,618,328	)	$	6,717,995

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2019

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	98,943	$	25,249	$	—		$	124,192
Accounts receivable, net		—		266,864		72,911		—			339,775
Other current assets		—		61,508		16,736		—			78,244
Total current assets		—		427,315		114,896		—			542,211
Property and equipment, net		—		1,313,830		1,910,204		—			3,224,034
Goodwill		—		1,992,344		456,787		—			2,449,131
Intangible assets, net		—		58,291		32,066		—			90,357
Deferred tax assets – noncurrent		1,403		—		3,339		(1,403	)		3,339
Operating lease right-of-use assets		—		97,396		404,441		—			501,837
Investment in subsidiaries		5,521,340		—		—		(5,521,340	)		—
Other assets		233,975		48,949		13,127		(227,818	)		68,233
Total assets	$	5,756,718	$	3,938,125	$	2,934,860	$	(5,750,561	)	$	6,879,142
Current liabilities:
Current portion of long-term debt	$	43,679	$	—	$	—	$	—		$	43,679
Accounts payable		—		87,165		39,880		—			127,045
Accrued salaries and benefits		—		89,483		33,069		—			122,552
Current portion of operating lease liabilities		—		17,967		11,173		—			29,140
Other accrued liabilities		33,323		22,672		85,165		—			141,160
Total current liabilities		77,002		217,287		169,287		—			463,576
Long-term debt		3,105,420		—		227,818		(227,818	)		3,105,420
Deferred tax liabilities – noncurrent		—		21,858		51,405		(1,403	)		71,860
Operating lease liabilities		—		85,365		416,887		—			502,252
Derivative instrument liabilities		68,915		—		—		—			68,915
Other liabilities		—		110,445		18,142		—			128,587
Total liabilities		3,251,337		434,955		883,539		(229,221	)		4,340,610
Redeemable noncontrolling interests		—		—		33,151		—			33,151
Total equity		2,505,381		3,503,170		2,018,170		(5,521,340	)		2,505,381
Total liabilities and equity	$	5,756,718	$	3,938,125	$	2,934,860	$	(5,750,561	)	$	6,879,142

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended March 31, 2020

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	474,612	$	308,198		$	—		$	782,810
Salaries, wages and benefits		4,979			261,603		173,734			—			440,316
Professional fees		—			28,558		34,742			—			63,300
Supplies		—			20,859		11,112			—			31,971
Rents and leases		—			8,883		11,941			—			20,824
Other operating expenses		—			63,819		34,710			—			98,529
Depreciation and amortization		—			21,046		20,634			—			41,680
Interest expense, net		14,460			24,159		4,166			—			42,785
Transaction-related expenses		—			1,525		2,024			—			3,549
Total expenses		19,439			430,452		293,063			—			742,954
(Loss) income before income taxes		(19,439	)		44,160		15,135			—			39,856
Equity in earnings of subsidiaries		48,353			—		—			(48,353	)		—
(Benefit from) provision for income taxes		(5,153	)		11,712		(770	)		—			5,789
Net income (loss)		34,067			32,448		15,905			(48,353	)		34,067
Net income attributable to noncontrolling interests		—			—		(604	)		—			(604	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	34,067		$	32,448	$	15,301		$	(48,353	)	$	33,463
Other comprehensive income:
Foreign currency translation gain		—			—		(122,000	)		—			(122,000	)
Loss on derivative instruments		43,746			—		—			—			43,746
Other comprehensive income (loss)		43,746			—		(122,000	)		—			(78,254	)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	77,813		$	32,448	$	(106,699	)	$	(48,353	)	$	(44,791	)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended March 31, 2019

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	459,818	$	300,799		$	—		$	760,617
Salaries, wages and benefits		6,101			254,942		168,536			—			429,579
Professional fees		—			25,368		31,639			—			57,007
Supplies		—			19,384		10,573			—			29,957
Rents and leases		—			8,403		11,904			—			20,307
Other operating expenses		—			59,390		34,475			—			93,865
Depreciation and amortization		—			19,605		20,975			—			40,580
Interest expense, net		19,578			23,018		5,534			—			48,130
Transaction-related expenses		—			3,218		1,103			—			4,321
Total expenses		25,679			413,328		284,739			—			723,746
(Loss) income before income taxes		(25,679	)		46,490		16,060			—			36,871
Equity in earnings of subsidiaries		48,157			—		—			(48,157	)		—
(Benefit from) provision for income taxes		(7,033	)		17,065		(2,672	)		—			7,360
Net income (loss)		29,511			29,425		18,732			(48,157	)		29,511
Net income attributable to noncontrolling interests		—			—		(40	)		—			(40	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	29,511		$	29,425	$	18,692		$	(48,157	)	$	29,471
Other comprehensive income:
Foreign currency translation gain		—			—		44,481			—			44,481
Loss on derivative instruments		(8,690	)		—		—			—			(8,690	)
Other comprehensive income (loss)		(8,690	)		—		44,481			—			35,791
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	20,821		$	29,425	$	63,173		$	(48,157	)	$	65,262

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Three Months Ended March 31, 2020

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	34,067		$	32,448		$	15,905		$	(48,353	)	$	34,067
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Equity in earnings of subsidiaries		(48,353	)		—			—			48,353			—
Depreciation and amortization		—			21,046			20,634			—			41,680
Amortization of debt issuance costs		3,050			—			—			—			3,050
Equity-based compensation expense		4,979			—			—			—			4,979
Deferred income taxes		101			11,044			141			—			11,286
Other		(101	)		(9	)		3			—			(107	)
Change in operating assets and liabilities:
Accounts receivable, net		—			(5,234	)		2,406			—			(2,828	)
Other current assets		—			(17,887	)		(1,244	)		—			(19,131	)
Other assets		82			(1,593	)		497			(82	)		(1,096	)
Accounts payable and other accrued liabilities		—			17,726			(39,481	)		—			(21,755	)
Accrued salaries and benefits		—			(7,411	)		1,381			—			(6,030	)
Other liabilities		—			2,803			(1,372	)		—			1,431
Net cash (used in) provided by operating activities		(6,175	)		52,933			(1,130	)		(82	)		45,546
Investing activities:
Cash paid for capital expenditures		—			(48,264	)		(21,283	)		—			(69,547	)
Cash paid for real estate acquisitions		—			(3,149	)		—			—			(3,149	)
Proceeds from sale of property and equipment		—			207			—			—			207
Other		—			(1,672	)		—			—			(1,672	)
Net cash used in investing activities		—			(52,878	)		(21,283	)		—			(74,161	)
Financing activities:
Principal payments on long-term debt		(10,621	)		—			(82	)		82			(10,621	)
Common stock withheld for minimum statutory taxes, net		(1,402	)		—			—			—			(1,402	)
Distributions to noncontrolling interests		—			—			(264	)		—			(264	)
Other		—			(423	)		(720	)		—			(1,143	)
Cash provided by (used in) intercompany activity		18,198			(47,235	)		29,037			—			—
Net cash provided by (used in) in financing activities		6,175			(47,658	)		27,971			82			(13,430	)
Effect of exchange rate changes on cash		—			—			(1,143	)		—			(1,143	)
Net (decrease) increase in cash and cash equivalents		—			(47,603	)		4,415			—			(43,188	)
Cash and cash equivalents at beginning of the period		—			98,943			25,249			—			124,192
Cash and cash equivalents at end of the period	$	—		$	51,340		$	29,664		$	—		$	81,004

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Three Months Ended March 31, 2019

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	29,511		$	29,425		$	18,732		$	(48,157	)	$	29,511
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Equity in earnings of subsidiaries		(48,157	)		—			—			48,157			—
Depreciation and amortization		—			19,605			20,975			—			40,580
Amortization of debt issuance costs		2,888			—			—			—			2,888
Equity-based compensation expense		6,101			—			—			—			6,101
Deferred income taxes		(254	)		(678	)		266			—			(666	)
Other		1,993			253			(59	)		—			2,187
Change in operating assets and liabilities:
Accounts receivable, net		—			(15,693	)		3,713			—			(11,980	)
Other current assets		—			(5,484	)		(391	)		—			(5,875	)
Other assets		2,665			(353	)		648			(2,665	)		295
Accounts payable and other accrued liabilities		—			(7,100	)		(8,601	)		—			(15,701	)
Accrued salaries and benefits		—			(7,872	)		2,023			—			(5,849	)
Other liabilities		—			3,317			(1,135	)		—			2,182
Net cash (used in) provided by operating activities		(5,253	)		15,420			36,171			(2,665	)		43,673
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(40,400	)		—			—			(40,400	)
Cash paid for capital expenditures		—			(45,231	)		(24,017	)		—			(69,248	)
Cash paid for real estate acquisitions		—			(1,066	)		—			—			(1,066	)
Proceeds from sale of property and equipment		—			836			92			—			928
Other		—			(315	)		—			—			(315	)
Net cash used in investing activities		—			(86,176	)		(23,925	)		—			(110,101	)
Financing activities:
Borrowings on revolving credit facility		71,573			—			—			—			71,573
Principal payments on long-term debt		(8,246	)		—			(2,665	)		2,665			(8,246	)
Common stock withheld for minimum statutory taxes, net		(1,327	)		—			—			—			(1,327	)
Other		(2,375	)		(442	)		(680	)		—			(3,497	)
Cash (used in) provided by intercompany activity		(54,372	)		56,570			(2,198	)		—			—
Net cash provided by (used in) in financing activities		5,253			56,128			(5,543	)		2,665			58,503
Effect of exchange rate changes on cash		—			—			1,099			—			1,099
Net (decrease) increase in cash and cash equivalents		—			(14,628	)		7,802			—			(6,826	)
Cash and cash equivalents at beginning of the period		—			32,471			18,039			—			50,510
Cash and cash equivalents at end of the period	$	—		$	17,843		$	25,841		$	—		$	43,684

Subsequent Events

3 Months Ended

Mar. 31, 2020

Subsequent Events [Abstract]

Subsequent Events

21.	Subsequent Events

On April 21, 2020, the Company entered into the Thirteenth Amendment to the Amended and Restated Credit Agreement. The Thirteenth Amendment amended the Consolidated Leverage Ratio in the existing covenant, to increase the leverage ratio for the rest of 2020. Additionally, in early April 2020, the Company borrowed $100.0 million on its revolving line of credit to enhance its cash position in response to the potential impact of COVID-19 on the Company’s future liquidity.

As part of the CARES Act, the U.S. government announced it would offer $100 billion of relief to eligible healthcare providers. The Company received approximately $20 million of the initial funds distributed in April 2020. The Company is evaluating the terms and conditions and financial impact of any funds received under the CARES Act and other government relief programs.

Using existing authority and certain expanded authority under the CARES Act, the U.S. Department of Health and Human Services (“HHS”) has expanded CMS’ Accelerated and Advance Payment Program to a broader group of Medicare Part A and Part B providers for the duration of the COVID-19 pandemic. Under the program, our facilities may request up to 100% of their Medicare payment amount for a three-month period. The repayment of these accelerated/advanced payments does not begin until 120 days after the date of the issuance of the payment. Once the repayment period starts, the amounts previously advanced to the provider or supplier will be recouped from the provider’s or supplier’s new Medicare claims. Facilities will generally have 210 days from the date the accelerated or advance payment was made to repay the amounts that they owe. The Company applied for and received approximately $45 million in April 2020 from this program, which the Company expects to repay over a three-month period from August to November 2020.

Revenue (Tables)

3 Months Ended

Mar. 31, 2020

Summary of the Activity in Unearned Revenue in the U.K. Facilities

A summary of the activity in unearned revenue in the U.K. Facilities is as follows (in thousands):

Balance at December 31, 2019	$	36,579
Payments received		38,152
Revenue recognized		(42,787	)
Foreign currency translation loss		(1,891	)
Balance at March 31, 2020	$	30,053

U.S. Facilities [Member]

Schedule of Revenue Attributed to Each Category

The table below presents total U.S. revenue attributed to each category (in thousands):

	Three Months Ended March 31,
	2020		2019
Acute inpatient psychiatric facilities	$	239,414	$	216,597
Specialty treatment facilities		193,611		193,035
Residential treatment centers		70,434		73,224
Outpatient community-based facilities		5,758		5,104
Revenue	$	509,217	$	487,960

Schedule of Revenue and Percentage Generated by Each Payor Type

The following table presents revenue by payor type and as a percentage of revenue in our U.S. Facilities (in thousands):

	Three Months Ended March 31,
	2020					2019
	Amount		%			Amount		%
Commercial	$	143,142		28.1	%	$	139,427		28.6	%
Medicare		72,271		14.2	%		72,616		14.9	%
Medicaid		260,044		51.1	%		239,191		49.0	%
Self-Pay		27,034		5.3	%		31,732		6.5	%
Other		6,726		1.3	%		4,994		1.0	%
Revenue	$	509,217		100.0	%	$	487,960		100.0	%

U.K. Facilities [Member]

Schedule of Revenue Attributed to Each Category

The table below presents total U.K. revenue attributed to each category (in thousands):

	Three Months Ended March 31,
	2020		2019
Healthcare facilities	$	148,137	$	151,708
Education and Children’s Services		46,666		46,122
Adult Care facilities		78,790		74,827
Revenue	$	273,593	$	272,657

Schedule of Revenue and Percentage Generated by Each Payor Type

The following table presents revenue by payor type and as a percentage of revenue in our U.K. Facilities (in thousands):

	Three Months Ended March 31,
	2020					2019
	Amount		%			Amount		%
U.K. public funded sources	$	246,136		90.0	%	$	245,413		90.0	%
Self-Pay		26,915		9.8	%		26,814		9.8	%
Other		542		0.2	%		430		0.2	%
Revenue	$	273,593		100.0	%	$	272,657		100.0	%

Earnings Per Share (Tables)

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the three months ended March 31, 2020 and 2019 (in thousands, except per share amounts):

	Three Months Ended March 31,
	2020		2019
Numerator:
Net income attributable to Acadia Healthcare Company, Inc.	$	33,463	$	29,471
Denominator:
Weighted average shares outstanding for basic earnings per share		87,765		87,505
Effect of dilutive instruments		206		189
Shares used in computing diluted earnings per common share		87,971		87,694
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$	0.38	$	0.34
Diluted	$	0.38	$	0.34

Acquisitions (Tables)

3 Months Ended

Mar. 31, 2020

Business Combinations [Abstract]

	Three Months Ended March 31,
	2020		2019
Termination, restructuring, sale and strategic review costs	$	2,221	$	2,282
Legal, accounting and other acquisition-related costs		1,328		796
Management transition costs		—		1,243
	$	3,549	$	4,321

Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2020

Property Plant And Equipment [Abstract]

Summary of Property and Equipment

Property and equipment consisted of the following at March 31, 2020 and December 31, 2019 (in thousands):

	March 31, 2020			December 31, 2019
Land	$	429,601		$	448,716
Building and improvements		2,738,302			2,746,111
Equipment		502,246			516,769
Construction in progress		229,058			254,213
		3,899,207			3,965,809
Less: accumulated depreciation		(747,468	)		(741,775	)
Property and equipment, net	$	3,151,739		$	3,224,034

Other Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2020

Goodwill And Intangible Assets Disclosure [Abstract]

Other Identifiable Intangible Assets and Related Accumulated Amortization

Other identifiable intangible assets and related accumulated amortization consisted of the following at March 31, 2020 and December 31, 2019 (in thousands):

	Gross Carrying Amount				Accumulated Amortization
	March 31, 2020		December 31, 2019		March 31, 2020			December 31, 2019
Intangible assets subject to amortization:
Contract intangible assets	$	2,100	$	2,100	$	(2,100	)	$	(2,100	)
Non-compete agreements		1,131		1,131		(1,131	)		(1,131	)
		3,231		3,231		(3,231	)		(3,231	)
Intangible assets not subject to amortization:
Licenses and accreditations		12,429		12,455		—			—
Trade names		59,532		60,831		—			—
Certificates of need		17,091		17,071		—			—
		89,052		90,357		—			—
Total	$	92,283	$	93,588	$	(3,231	)	$	(3,231	)

Leases (Tables)

3 Months Ended

Mar. 31, 2020

Leases [Abstract]

Schedule of Leases on Condensed Consolidated Balance Sheet

The Company recorded the following at March 31, 2020 and December 31, 2019 on the condensed consolidated balance sheets (in thousands):

Right-of-Use Assets	Balance Sheet Classification	March 31, 2020		December 31, 2019
Finance lease right-of-use assets	Property and equipment, net	$	43,760	$	44,370
Operating lease right-of-use assets	Operating lease right-of-use assets		476,028		501,837
Total		$	519,788	$	546,207

Lease Liabilities	Balance Sheet Classification	March 31, 2020		December 31, 2019
Current:
Finance lease liabilities	Other accrued liabilities	$	6,637	$	6,819
Operating lease liabilities	Current portion of operating lease liabilities		29,671		29,140
Noncurrent:
Finance lease liabilities	Other liabilities		43,295		43,662
Operating lease liabilities	Operating lease liabilities		474,746		502,252
Total		$	554,349	$	581,873

Schedule of Weighted-average Remaining Lease Terms and Discount Rates

Weighted-average remaining lease terms and discount rates were as follows at March 31, 2020 and December 31, 2019:

	March 31, 2020			December 31, 2019
Weighted-average remaining lease term (in years):
Finance	6.7			6.9
Operating		19.0		19.4

Weighted-average discount rate:
Finance		6.4	%		6.4	%
Operating		6.3	%		6.3	%

Schedule of Lease Cost

The Company recorded the following lease costs for the three months ended March 31, 2020 and 2019 (in thousands):

	Three Months Ended March 31,
	2020		2019
Finance lease costs:
Depreciation of leased assets		1,137		1,123
Interest of lease liabilities		997		997
Total finance lease costs	$	2,134	$	2,120

Operating lease costs		16,481		16,529
Variable lease costs		1,310		886
Short term lease costs		1,147		1,447
Other lease costs		1,886		1,445
Total rents and leases	$	20,824	$	20,307

Total lease costs	$	22,958	$	22,427

Schedule of Undiscounted Cash Flows for Finance and Operating Leases

Undiscounted cash flows for finance and operating leases recorded on the condensed consolidated balance sheets were as follows at March 31, 2020 (in thousands):

	Finance Leases		Operating Leases
For the nine months ending December 31, 2020	$	5,549	$	45,846
2021		35,726		58,023
2022		2,845		52,956
2023		1,620		48,544
2024		1,027		46,312
Thereafter		25,088		650,931
Total minimum lease payments		71,855		902,612
Less: amount of lease payments representing interest		21,923		398,195
Present value of future minimum lease payments		49,932		504,417
Less: Current portion of lease liabilities		6,637		29,671
Noncurrent lease liabilities	$	43,295	$	474,746

Schedule of Supplemental Data

Supplemental data for the three months ended March 31, 2020 and 2019 was as follows (in thousands):

	Three Months Ended March 31,
	2020		2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$	15,836	$	15,809
Operating cash flows for finance leases	$	997	$	997
Financing cash flows for finance leases	$	878	$	846

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	6,082	$	3,662
Finance leases	$	953	$	1,027

Long-Term Debt (Tables)

3 Months Ended

Mar. 31, 2020

Debt Disclosure [Abstract]

Components of Long-Term Debt

Long-term debt consisted of the following (in thousands):

	March 31, 2020			December 31, 2019
Amended and Restated Senior Credit Facility:
Senior Secured Term A Loan	$	339,625		$	346,750
Senior Secured Term B Loans		1,335,432			1,338,928
Senior Secured Revolving Line of Credit		—			—
6.125% Senior Notes due 2021		150,000			150,000
5.125% Senior Notes due 2022		300,000			300,000
5.625% Senior Notes due 2023		650,000			650,000
6.500% Senior Notes due 2024		390,000			390,000
Other long-term debt		4,533			4,821
Less: unamortized debt issuance costs, discount and premium		(28,698	)		(31,400	)
		3,140,892			3,149,099
Less: current portion		(196,072	)		(43,679	)
Long-term debt	$	2,944,820		$	3,105,420

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Equity-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock Option Activity

Stock option activity during 2019 and 2020 was as follows (aggregate intrinsic value in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Options outstanding at January 1, 2019		1,199,540		$	44.64		7.26	$	2,717
Options granted		605,200			28.50		9.21		1,343
Options exercised		(55,671	)		19.05	N/A			658
Options cancelled		(389,001	)		40.84	N/A		N/A
Options outstanding at December 31, 2019		1,360,068			39.40		7.57		1,650
Options granted		443,200			33.72		9.91		—
Options exercised		—			—	N/A			—
Options cancelled		(105,462	)		41.00	N/A		N/A
Options outstanding at March 31, 2020		1,697,806		$	37.81		7.97	$	659
Options exercisable at December 31, 2019		513,290		$	48.08		5.88	$	512
Options exercisable at March 31, 2020		702,956		$	44.08		6.36	$	479

Schedule of Stock Options Valuation Assumptions

The following table summarizes the grant-date fair value of options and the assumptions used to develop the fair value estimates for options granted during the three months ended March 31, 2020 and year ended December 31, 2019:

	March 31, 2020			December 31, 2019
Weighted average grant-date fair value of options	$	12.29		$	17.59
Risk-free interest rate		1.6	%		2.4	%
Expected volatility		39	%		38	%
Expected life (in years)		5.0			5.0

Restricted Stock Activity

Restricted stock activity during 2019 and 2020 was as follows:

	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2019		805,057		$	42.40
Granted		700,937			28.77
Cancelled		(389,684	)		33.50
Vested		(311,174	)		44.23
Unvested at December 31, 2019		805,136		$	34.14
Granted		511,006			25.37
Cancelled		(57,782	)		35.55
Vested		(160,398	)		36.73
Unvested at March 31, 2020		1,097,962		$	29.61

Restricted Stock Unit Activity

Restricted stock unit activity during 2019 and 2020 was as follows:

	Number of Units			Weighted Average Grant-Date Fair Value
Unvested at January 1, 2019		484,111		$	44.52
Granted		234,408			34.54
Cancelled		(271,162	)		45.17
Vested		—			—
Unvested at December 31, 2019		447,357		$	38.89
Granted		583,680			10.60
Cancelled		(10,123	)		42.09
Vested		(12,691	)		42.09
Unvested at March 31, 2020		1,008,223		$	22.44

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liabilities

	Carrying Amount						Fair Value
	March 31, 2020			December 31, 2019			March 31, 2020			December 31, 2019
Amended and Restated Senior Credit Facility	$	1,659,098		$	1,668,062		$	1,659,098		$	1,668,062
6.125% Senior Notes due 2021	$	149,409		$	149,254		$	144,927		$	149,441
5.125% Senior Notes due 2022	$	297,973		$	297,761		$	283,998		$	299,994
5.625% Senior Notes due 2023	$	645,156		$	644,771		$	607,995		$	655,249
6.500% Senior Notes due 2024	$	384,723		$	384,430		$	374,143		$	398,366
Other long-term debt	$	4,533		$	4,821		$	4,533		$	4,821
Derivative instrument liabilities	$	(9,015	)	$	(68,915	)	$	(9,015	)	$	(68,915	)

Noncontrolling Interests (Tables)

3 Months Ended

Mar. 31, 2020

Noncontrolling Interest [Abstract]

Summary of Redeemable Noncontrolling Interests

The components of redeemable noncontrolling interests are as follows (in thousands):

Balance at December 31, 2019	$	33,151
Net income attributable to noncontrolling interests		604
Dividend payments to noncontrolling interests		(264	)
Balance at March 31, 2020	$	33,491

Other Current Assets (Tables)

3 Months Ended

Mar. 31, 2020

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Other Current Assets

Other current assets consisted of the following (in thousands):

	March 31, 2020		December 31, 2019
Prepaid expenses	$	22,161	$	23,708
Cost report receivable		14,402		13,723
Other receivables		14,257		16,097
Workers’ compensation deposits – current portion		10,000		10,000
Income taxes receivable		9,358		5,579
Insurance receivable – current portion		5,739		3,030
Inventory		4,882		4,759
Other		1,644		1,348
Other current assets	$	82,443	$	78,244

Other Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2020

Other Liabilities Disclosure [Abstract]

Summary of Other Accrued Liabilities

Other accrued liabilities consisted of the following (in thousands):

	March 31, 2020		December 31, 2019
Accrued expenses	$	41,131	$	50,614
Unearned income		31,631		38,475
Accrued interest		11,660		33,323
Finance lease liabilities		6,637		6,819
Insurance liability – current portion		4,731		4,731
Accrued property taxes		4,222		4,755
Other		4,346		2,443
Other accrued liabilities	$	104,358	$	141,160

Segment Information (Tables)

3 Months Ended

Mar. 31, 2020

Summary of Reconciliation of Segment EBITDA to Income before Income Taxes

The following tables set forth the financial information by operating segment, including a reconciliation of Segment EBITDA to income before income taxes (in thousands):

	Three Months Ended March 31,
	2020			2019
Revenue:
U.S. Facilities	$	509,217		$	487,960
U.K. Facilities		273,593			272,657
Corporate and Other		—			—
	$	782,810		$	760,617
Segment EBITDA (1):
U.S. Facilities	$	120,074		$	119,008
U.K. Facilities		36,168			40,056
Corporate and Other		(23,393	)		(23,061	)
	$	132,849		$	136,003

	Three Months Ended March 31,
	2020			2019
Segment EBITDA (1)	$	132,849		$	136,003
Less:
Equity-based compensation expense		(4,979	)		(6,101	)
Transaction-related expenses		(3,549	)		(4,321	)
Interest expense, net		(42,785	)		(48,130	)
Depreciation and amortization		(41,680	)		(40,580	)
Income before income taxes	$	39,856		$	36,871

Summary of Assets by Operating Segment

	March 31, 2020		December 31, 2019
Assets (2):
U.S. Facilities	$	4,083,825	$	4,037,968
U.K. Facilities		2,443,498		2,610,357
Corporate and Other		190,672		230,817
	$	6,717,995	$	6,879,142

(1)

(2)

Goodwill [Member]

Summary of Assets by Operating Segment

	U.S. Facilities			U.K. Facilities			Corporate and Other		Consolidated
Goodwill:
Balance at January 1, 2020
Goodwill	$	2,085,104		$	689,902		$	—	$	2,775,006
Accumulated impairment loss		—			(325,875	)		—		(325,875	)
Net goodwill at January 1, 2020		2,085,104			364,027			—		2,449,131
Prior period purchase price adjustments		(13	)		—			—		(13	)
Foreign currency translation gain		—			(22,418	)		—		(22,418	)
Balance at March 31, 2020
Goodwill		2,085,091			667,484			—		2,752,575
Accumulated impairment loss		—			(325,875	)		—		(325,875	)
Net goodwill at March 31, 2020	$	2,085,091		$	341,609		$	—	$	2,426,700

Accumulated Other Comprehensive Loss (Tables)

3 Months Ended

Mar. 31, 2020

Equity [Abstract]

Components of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

	Foreign Currency Translation Adjustments			Change in Fair Value of Derivative Instruments		Pension Plan			Total
Balance at December 31, 2019	$	(434,633	)	$	24,958	$	(5,209	)	$	(414,884	)
Foreign currency translation (loss) gain		(122,321	)		—		321			(122,000	)
Gain on derivative instruments, net of tax of $16.3 million		—			43,746		—			43,746
Balance at March 31, 2020	$	(556,954	)	$	68,704	$	(4,888	)	$	(493,138	)

Financial Information for the Company and Its Subsidiaries (Tables)

3 Months Ended

Mar. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summary of Condensed Consolidating Balance Sheets

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

March 31, 2020

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	51,340	$	29,664	$	—		$	81,004
Accounts receivable, net		—		272,098		67,407		—			339,505
Other current assets		—		65,346		17,097		—			82,443
Total current assets		—		388,784		114,168		—			502,952
Property and equipment, net		—		1,348,045		1,803,694		—			3,151,739
Goodwill		—		1,992,332		434,368		—			2,426,700
Intangible assets, net		—		58,312		30,740		—			89,052
Deferred tax assets		1,303		—		3,307		(1,303	)		3,307
Investment in subsidiaries		5,390,417		—		—		(5,390,417	)		—
Operating lease right-of-use assets		—		98,166		377,862		—			476,028
Other assets		234,014		48,597		12,214		(226,608	)		68,217
Total assets	$	5,625,734	$	3,934,236	$	2,776,353	$	(5,618,328	)	$	6,717,995

Current liabilities:
Current portion of long-term debt	$	196,072	$	—	$	—	$	—		$	196,072
Accounts payable		—		97,196		37,497		—			134,693
Accrued salaries and benefits		—		82,072		32,718		—			114,790
Current portion of operating lease liabilities		—		18,571		11,100		—			29,671
Other accrued liabilities		11,660		26,021		66,677		—			104,358
Total current liabilities		207,732		223,860		147,992		—			579,584
Long-term debt		2,944,820		—		226,608		(226,608	)		2,944,820
Deferred tax liabilities		—		41,087		45,621		(1,303	)		85,405
Operating lease liabilities		—		85,577		389,169		—			474,746
Derivative instrument liabilities		9,015		—		—		—			9,015
Other liabilities		—		110,923		15,844		—			126,767
Total liabilities		3,161,567		461,447		825,234		(227,911	)		4,220,337
Redeemable noncontrolling interests		—		—		33,491		—			33,491
Total equity		2,464,167		3,472,789		1,917,628		(5,390,417	)		2,464,167
Total liabilities and equity	$	5,625,734	$	3,934,236	$	2,776,353	$	(5,618,328	)	$	6,717,995

Acadia Healthcare Company, Inc.

Condensed Consolidating Balance Sheets

December 31, 2019

(In thousands)

	Parent		Combined Subsidiary Guarantors		Combined Non- Guarantors		Consolidating Adjustments			Total Consolidated Amounts
Current assets:
Cash and cash equivalents	$	—	$	98,943	$	25,249	$	—		$	124,192
Accounts receivable, net		—		266,864		72,911		—			339,775
Other current assets		—		61,508		16,736		—			78,244
Total current assets		—		427,315		114,896		—			542,211
Property and equipment, net		—		1,313,830		1,910,204		—			3,224,034
Goodwill		—		1,992,344		456,787		—			2,449,131
Intangible assets, net		—		58,291		32,066		—			90,357
Deferred tax assets – noncurrent		1,403		—		3,339		(1,403	)		3,339
Operating lease right-of-use assets		—		97,396		404,441		—			501,837
Investment in subsidiaries		5,521,340		—		—		(5,521,340	)		—
Other assets		233,975		48,949		13,127		(227,818	)		68,233
Total assets	$	5,756,718	$	3,938,125	$	2,934,860	$	(5,750,561	)	$	6,879,142
Current liabilities:
Current portion of long-term debt	$	43,679	$	—	$	—	$	—		$	43,679
Accounts payable		—		87,165		39,880		—			127,045
Accrued salaries and benefits		—		89,483		33,069		—			122,552
Current portion of operating lease liabilities		—		17,967		11,173		—			29,140
Other accrued liabilities		33,323		22,672		85,165		—			141,160
Total current liabilities		77,002		217,287		169,287		—			463,576
Long-term debt		3,105,420		—		227,818		(227,818	)		3,105,420
Deferred tax liabilities – noncurrent		—		21,858		51,405		(1,403	)		71,860
Operating lease liabilities		—		85,365		416,887		—			502,252
Derivative instrument liabilities		68,915		—		—		—			68,915
Other liabilities		—		110,445		18,142		—			128,587
Total liabilities		3,251,337		434,955		883,539		(229,221	)		4,340,610
Redeemable noncontrolling interests		—		—		33,151		—			33,151
Total equity		2,505,381		3,503,170		2,018,170		(5,521,340	)		2,505,381
Total liabilities and equity	$	5,756,718	$	3,938,125	$	2,934,860	$	(5,750,561	)	$	6,879,142

Summary of Condensed Consolidating Statement of Comprehensive Income (Loss)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended March 31, 2020

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	474,612	$	308,198		$	—		$	782,810
Salaries, wages and benefits		4,979			261,603		173,734			—			440,316
Professional fees		—			28,558		34,742			—			63,300
Supplies		—			20,859		11,112			—			31,971
Rents and leases		—			8,883		11,941			—			20,824
Other operating expenses		—			63,819		34,710			—			98,529
Depreciation and amortization		—			21,046		20,634			—			41,680
Interest expense, net		14,460			24,159		4,166			—			42,785
Transaction-related expenses		—			1,525		2,024			—			3,549
Total expenses		19,439			430,452		293,063			—			742,954
(Loss) income before income taxes		(19,439	)		44,160		15,135			—			39,856
Equity in earnings of subsidiaries		48,353			—		—			(48,353	)		—
(Benefit from) provision for income taxes		(5,153	)		11,712		(770	)		—			5,789
Net income (loss)		34,067			32,448		15,905			(48,353	)		34,067
Net income attributable to noncontrolling interests		—			—		(604	)		—			(604	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	34,067		$	32,448	$	15,301		$	(48,353	)	$	33,463
Other comprehensive income:
Foreign currency translation gain		—			—		(122,000	)		—			(122,000	)
Loss on derivative instruments		43,746			—		—			—			43,746
Other comprehensive income (loss)		43,746			—		(122,000	)		—			(78,254	)
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	77,813		$	32,448	$	(106,699	)	$	(48,353	)	$	(44,791	)

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Comprehensive Income (Loss)

Three Months Ended March 31, 2019

(In thousands)

	Parent			Combined Subsidiary Guarantors		Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Revenue	$	—		$	459,818	$	300,799		$	—		$	760,617
Salaries, wages and benefits		6,101			254,942		168,536			—			429,579
Professional fees		—			25,368		31,639			—			57,007
Supplies		—			19,384		10,573			—			29,957
Rents and leases		—			8,403		11,904			—			20,307
Other operating expenses		—			59,390		34,475			—			93,865
Depreciation and amortization		—			19,605		20,975			—			40,580
Interest expense, net		19,578			23,018		5,534			—			48,130
Transaction-related expenses		—			3,218		1,103			—			4,321
Total expenses		25,679			413,328		284,739			—			723,746
(Loss) income before income taxes		(25,679	)		46,490		16,060			—			36,871
Equity in earnings of subsidiaries		48,157			—		—			(48,157	)		—
(Benefit from) provision for income taxes		(7,033	)		17,065		(2,672	)		—			7,360
Net income (loss)		29,511			29,425		18,732			(48,157	)		29,511
Net income attributable to noncontrolling interests		—			—		(40	)		—			(40	)
Net income (loss) attributable to Acadia Healthcare Company, Inc.	$	29,511		$	29,425	$	18,692		$	(48,157	)	$	29,471
Other comprehensive income:
Foreign currency translation gain		—			—		44,481			—			44,481
Loss on derivative instruments		(8,690	)		—		—			—			(8,690	)
Other comprehensive income (loss)		(8,690	)		—		44,481			—			35,791
Comprehensive income (loss) attributable to Acadia Healthcare Company, Inc.	$	20,821		$	29,425	$	63,173		$	(48,157	)	$	65,262

Summary of Condensed Consolidating Statement of Cash Flows

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Three Months Ended March 31, 2020

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	34,067		$	32,448		$	15,905		$	(48,353	)	$	34,067
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Equity in earnings of subsidiaries		(48,353	)		—			—			48,353			—
Depreciation and amortization		—			21,046			20,634			—			41,680
Amortization of debt issuance costs		3,050			—			—			—			3,050
Equity-based compensation expense		4,979			—			—			—			4,979
Deferred income taxes		101			11,044			141			—			11,286
Other		(101	)		(9	)		3			—			(107	)
Change in operating assets and liabilities:
Accounts receivable, net		—			(5,234	)		2,406			—			(2,828	)
Other current assets		—			(17,887	)		(1,244	)		—			(19,131	)
Other assets		82			(1,593	)		497			(82	)		(1,096	)
Accounts payable and other accrued liabilities		—			17,726			(39,481	)		—			(21,755	)
Accrued salaries and benefits		—			(7,411	)		1,381			—			(6,030	)
Other liabilities		—			2,803			(1,372	)		—			1,431
Net cash (used in) provided by operating activities		(6,175	)		52,933			(1,130	)		(82	)		45,546
Investing activities:
Cash paid for capital expenditures		—			(48,264	)		(21,283	)		—			(69,547	)
Cash paid for real estate acquisitions		—			(3,149	)		—			—			(3,149	)
Proceeds from sale of property and equipment		—			207			—			—			207
Other		—			(1,672	)		—			—			(1,672	)
Net cash used in investing activities		—			(52,878	)		(21,283	)		—			(74,161	)
Financing activities:
Principal payments on long-term debt		(10,621	)		—			(82	)		82			(10,621	)
Common stock withheld for minimum statutory taxes, net		(1,402	)		—			—			—			(1,402	)
Distributions to noncontrolling interests		—			—			(264	)		—			(264	)
Other		—			(423	)		(720	)		—			(1,143	)
Cash provided by (used in) intercompany activity		18,198			(47,235	)		29,037			—			—
Net cash provided by (used in) in financing activities		6,175			(47,658	)		27,971			82			(13,430	)
Effect of exchange rate changes on cash		—			—			(1,143	)		—			(1,143	)
Net (decrease) increase in cash and cash equivalents		—			(47,603	)		4,415			—			(43,188	)
Cash and cash equivalents at beginning of the period		—			98,943			25,249			—			124,192
Cash and cash equivalents at end of the period	$	—		$	51,340		$	29,664		$	—		$	81,004

Acadia Healthcare Company, Inc.

Condensed Consolidating Statement of Cash Flows

Three Months Ended March 31, 2019

(In thousands)

	Parent			Combined Subsidiary Guarantors			Combined Non- Guarantors			Consolidating Adjustments			Total Consolidated Amounts
Operating activities:
Net income (loss)	$	29,511		$	29,425		$	18,732		$	(48,157	)	$	29,511
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Equity in earnings of subsidiaries		(48,157	)		—			—			48,157			—
Depreciation and amortization		—			19,605			20,975			—			40,580
Amortization of debt issuance costs		2,888			—			—			—			2,888
Equity-based compensation expense		6,101			—			—			—			6,101
Deferred income taxes		(254	)		(678	)		266			—			(666	)
Other		1,993			253			(59	)		—			2,187
Change in operating assets and liabilities:
Accounts receivable, net		—			(15,693	)		3,713			—			(11,980	)
Other current assets		—			(5,484	)		(391	)		—			(5,875	)
Other assets		2,665			(353	)		648			(2,665	)		295
Accounts payable and other accrued liabilities		—			(7,100	)		(8,601	)		—			(15,701	)
Accrued salaries and benefits		—			(7,872	)		2,023			—			(5,849	)
Other liabilities		—			3,317			(1,135	)		—			2,182
Net cash (used in) provided by operating activities		(5,253	)		15,420			36,171			(2,665	)		43,673
Investing activities:
Cash paid for acquisitions, net of cash acquired		—			(40,400	)		—			—			(40,400	)
Cash paid for capital expenditures		—			(45,231	)		(24,017	)		—			(69,248	)
Cash paid for real estate acquisitions		—			(1,066	)		—			—			(1,066	)
Proceeds from sale of property and equipment		—			836			92			—			928
Other		—			(315	)		—			—			(315	)
Net cash used in investing activities		—			(86,176	)		(23,925	)		—			(110,101	)
Financing activities:
Borrowings on revolving credit facility		71,573			—			—			—			71,573
Principal payments on long-term debt		(8,246	)		—			(2,665	)		2,665			(8,246	)
Common stock withheld for minimum statutory taxes, net		(1,327	)		—			—			—			(1,327	)
Other		(2,375	)		(442	)		(680	)		—			(3,497	)
Cash (used in) provided by intercompany activity		(54,372	)		56,570			(2,198	)		—			—
Net cash provided by (used in) in financing activities		5,253			56,128			(5,543	)		2,665			58,503
Effect of exchange rate changes on cash		—			—			1,099			—			1,099
Net (decrease) increase in cash and cash equivalents		—			(14,628	)		7,802			—			(6,826	)
Cash and cash equivalents at beginning of the period		—			32,471			18,039			—			50,510
Cash and cash equivalents at end of the period	$	—		$	17,843		$	25,841		$	—		$	43,684

Description of Business and Basis of Presentation - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2020 Facility Bed State
Accounting Policies [Abstract]
Number of facilities \| Facility	588
Number of beds \| Bed	18,200
Number of operating states \| State	40

Revenue - Schedule of U.S. Revenue Attributed to Each Category (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 782,810	$ 760,617
U.S. Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	509,217	487,960
U.S. Facilities [Member] \| Acute Inpatient Psychiatric Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	239,414	216,597
U.S. Facilities [Member] \| Specialty Treatment Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	193,611	193,035
U.S. Facilities [Member] \| Residential Treatment Centers [Member]
Disaggregation of Revenue [Line Items]
Revenue	70,434	73,224
U.S. Facilities [Member] \| Outpatient Community-Based Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 5,758	$ 5,104

Revenue - Schedule of U.S. Revenue and Percentage Generated by Each Payor Type (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 782,810	$ 760,617
U.S. Facilities [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 509,217	$ 487,960
Revenue, Percentage	100.00%	100.00%
U.S. Facilities [Member] \| Commercial [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 143,142	$ 139,427
Revenue, Percentage	28.10%	28.60%
U.S. Facilities [Member] \| Medicare [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 72,271	$ 72,616
Revenue, Percentage	14.20%	14.90%
U.S. Facilities [Member] \| Medicaid [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 260,044	$ 239,191
Revenue, Percentage	51.10%	49.00%
U.S. Facilities [Member] \| Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 27,034	$ 31,732
Revenue, Percentage	5.30%	6.50%
U.S. Facilities [Member] \| Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 6,726	$ 4,994
Revenue, Percentage	1.30%	1.00%

Revenue - Schedule of U.K. Revenue Attributed to Each Category (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 782,810	$ 760,617
U.K. Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	273,593	272,657
U.K. Facilities [Member] \| Health Care Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	148,137	151,708
U.K. Facilities [Member] \| Education and Children's Services [Member]
Disaggregation of Revenue [Line Items]
Revenue	46,666	46,122
U.K. Facilities [Member] \| Adult Care Facilities [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 78,790	$ 74,827

Revenue - Schedule of U.K. Revenue and Percentage Generated by Each Payor Type (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 782,810	$ 760,617
U.K. Facilities [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 273,593	$ 272,657
Revenue, Percentage	100.00%	100.00%
U.K. Facilities [Member] \| U.K. Public Funded Sources [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 246,136	$ 245,413
Revenue, Percentage	90.00%	90.00%
U.K. Facilities [Member] \| Self-Pay [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 26,915	$ 26,814
Revenue, Percentage	9.80%	9.80%
U.K. Facilities [Member] \| Other [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 542	$ 430
Revenue, Percentage	0.20%	0.20%

Revenue - Summary of the Activity in Unearned Revenue (Detail) - U.K. Facilities [Member] - Unearned Revenue [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($)
Disaggregation of Revenue [Line Items]
Beginning Balance	$ 36,579
Payments received	38,152
Revenue recognized	(42,787)
Foreign currency translation loss	(1,891)
Ending Balance	$ 30,053

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019
Numerator:
Net income attributable to Acadia Healthcare Company, Inc.	$ 33,463	$ (11,254)	$ 42,566	$ 48,140	$ 29,471
Denominator:
Weighted average shares outstanding for basic earnings per share	87,765				87,505
Effect of dilutive instruments	206				189
Shares used in computing diluted earnings per common share	87,971				87,694
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:
Basic	$ 0.38				$ 0.34
Diluted	$ 0.38				$ 0.34

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Earnings Per Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Excluded common stock for computation of diluted earnings per share	2.9	2.6

Acquisitions - Additional Information (Detail) $ in Millions	Apr. 01, 2019 USD ($) Bed	Feb. 15, 2019 USD ($) Bed Center	Mar. 31, 2020 Bed
Business Acquisition [Line Items]
Number of beds \| Bed			18,200
Bradford [Member]
Business Acquisition [Line Items]
Number of beds \| Bed	46
Business acquisition cash consideration \| $	$ 4.5
Whittier Pavilion [Member] \| Massachusetts [Member]
Business Acquisition [Line Items]
Number of beds \| Bed		71
Business acquisition cash consideration \| $		$ 17.9
Mission Treatment [Member] \| California, Nevada, Arizona and Oklahoma [Member]
Business Acquisition [Line Items]
Business acquisition cash consideration \| $		$ 22.5
Number of comprehensive treatment centers operates \| Center		9

Acquisitions - Transaction Related Expenses as Incurred (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Business Combinations [Abstract]
Termination, restructuring, sale and strategic review costs	$ 2,221	$ 2,282
Legal, accounting and other acquisition-related costs	1,328	796
Management transition costs		1,243
Transaction-related expenses	$ 3,549	$ 4,321

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 3,899,207	$ 3,965,809
Less: accumulated depreciation	(747,468)	(741,775)
Property and equipment, net	3,151,739	3,224,034
Land [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	429,601	448,716
Building and Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,738,302	2,746,111
Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	502,246	516,769
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 229,058	$ 254,213

Property and Equipment - Additional Information (Detail) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Other Assets [Member]
Property Plant And Equipment [Line Items]
Assets held for sale	$ 30.3	$ 31.1

Other Intangible Assets - Other Identifiable Intangible Assets and Related Accumulated Amortization (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	$ 3,231	$ 3,231
Intangible assets not subject to amortization, Gross Carrying Amount	89,052	90,357
Total	92,283	93,588
Intangible assets subject to amortization, Accumulated Amortization	(3,231)	(3,231)
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Total	(3,231)	(3,231)
Licenses and Accreditations [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	12,429	12,455
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Trade Names [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	59,532	60,831
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Certificates of Need [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets not subject to amortization, Gross Carrying Amount	17,091	17,071
Intangible assets not subject to amortization, Accumulated Amortization	0	0
Contract Intangible Assets [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	2,100	2,100
Intangible assets subject to amortization, Accumulated Amortization	(2,100)	(2,100)
Non-Compete Agreements [Member]
Schedule Of Finite and Indefinite Lived Other Intangible Assets [Line Items]
Intangible assets subject to amortization, Gross Carrying Amount	1,131	1,131
Intangible assets subject to amortization, Accumulated Amortization	$ (1,131)	$ (1,131)

Leases - Additional Information (Detail)	3 Months Ended
Leases - Additional Information (Detail)	Mar. 31, 2020
Minimum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	5 years
Maximum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	30 years
Copiers and Equipment [Member] \| Minimum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	1 year
Copiers and Equipment [Member] \| Maximum [Member]
Lessee Lease Description [Line Items]
Lessee operating and finance lease term of contract	3 years

Leases - Schedule of Leases on Condensed Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Lessee Lease Description [Line Items]
Operating lease right-of-use assets	$ 476,028	$ 501,837
Total	519,788	546,207
Finance lease liabilities	6,637	6,819
Operating lease liabilities	29,671	29,140
Finance lease liabilities	43,295
Operating lease liabilities	474,746	502,252
Total	554,349	581,873
Property and Equipment, Net [Member]
Lessee Lease Description [Line Items]
Finance lease right-of-use assets	43,760	44,370
Operating Lease Right-of-use Assets [Member]
Lessee Lease Description [Line Items]
Operating lease right-of-use assets	476,028	501,837
Other Accrued Liabilities [Member]
Lessee Lease Description [Line Items]
Finance lease liabilities	6,637	6,819
Current Portion of Operating Lease Liabilities [Member]
Lessee Lease Description [Line Items]
Operating lease liabilities	29,671	29,140
Other Liabilities [Member]
Lessee Lease Description [Line Items]
Finance lease liabilities	43,295	43,662
Operating Lease Liabilities [Member]
Lessee Lease Description [Line Items]
Operating lease liabilities	$ 474,746	$ 502,252

Leases - Schedule of Weighted-average Remaining Lease Terms and Discount Rates (Detail)	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Finance lease, weighted average remaining lease term (years)	6 years 8 months 12 days	6 years 10 months 24 days
Operating lease, weighted average remaining term (years)	19 years	19 years 4 months 24 days
Finance lease, weighted average discount rate percent	6.40%	6.40%
Operating lease, weighted average discount rate percent	6.30%	6.30%

Leases - Schedule of Lease Cost (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Finance lease costs:
Depreciation of leased assets	$ 1,137	$ 1,123
Interest of lease liabilities	997	997
Total finance lease costs	2,134	2,120
Operating lease costs	16,481	16,529
Variable lease costs	1,310	886
Short term lease costs	1,147	1,447
Other lease costs	1,886	1,445
Total rents and leases	20,824	20,307
Total lease costs	$ 22,958	$ 22,427

Leases - Schedule of Undiscounted Cash Flows for Finance and Operating Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Finance Leases
For the nine months ending December 31, 2020	$ 5,549
2021	35,726
2022	2,845
2023	1,620
2024	1,027
Thereafter	25,088
Total minimum lease payments	71,855
Less: amount of lease payments representing interest	21,923
Present value of future minimum lease payments	49,932
Less: Current portion of lease liabilities	6,637	$ 6,819
Noncurrent lease liabilities	43,295
Operating Leases
For the nine months ending December 31, 2020	45,846
2021	58,023
2022	52,956
2023	48,544
2024	46,312
Thereafter	650,931
Total minimum lease payments	902,612
Less: amount of lease payments representing interest	398,195
Present value of future minimum lease payments	504,417
Current portion of operating lease liabilities	29,671	29,140
Operating lease liabilities	$ 474,746	$ 502,252

Leases - Schedule of Supplemental Data (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$ 15,836	$ 15,809
Operating cash flows for finance leases	997	997
Financing cash flows for finance leases	878	846
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	6,082	3,662
Finance leases	$ 953	$ 1,027

Long-Term Debt - Components of Long-Term Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Sep. 21, 2015
Debt Instrument [Line Items]
Other long-term debt	$ 4,533	$ 4,821
Less: unamortized debt issuance costs, discount and premium	(28,698)	(31,400)
Long-term debt	3,140,892	3,149,099
Less: current portion	(196,072)	(43,679)
Long-term debt	2,944,820	3,105,420
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Term A Loan [Member]
Debt Instrument [Line Items]
Senior Secured	339,625	346,750
Amended and Restated Senior Credit Facility [Member] \| Senior Secured Term B Loans [Member]
Debt Instrument [Line Items]
Senior Secured	1,335,432	1,338,928
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Senior Notes	150,000	150,000
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Senior Notes	300,000	300,000
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Senior Notes	650,000	650,000	$ 650,000
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Senior Notes	$ 390,000	$ 390,000

Long-Term Debt - Components of Long-Term Debt (Parenthetical) (Detail)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%					6.125%
Senior notes maturity year	2021	2021
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.125%	5.125%				5.125%
Senior notes maturity year	2022	2022
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%	5.625%		5.625%	5.625%
Senior notes maturity year	2023	2023
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.50%	6.50%	6.50%
Senior notes maturity year	2024	2024

Long-Term Debt (Amended and Restated Senior Credit Facility) - Additional Information (Detail) - USD ($) $ in Thousands							1 Months Ended	3 Months Ended						12 Months Ended
	Apr. 21, 2020	Feb. 27, 2019	Feb. 06, 2019	Dec. 15, 2015	Dec. 31, 2012	Apr. 01, 2011	Apr. 30, 2020	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 15, 2014
Debt Instrument [Line Items]
Borrowings on revolving credit facility									$ 71,573
Consolidated funded debt, unrestricted and unencumbered cash to consolidated EBITDA															$ 50,000
Eurodollar [Member]
Debt Instrument [Line Items]
Interest on borrowings								2.50%
Base Rate Loans [Member]
Debt Instrument [Line Items]
Interest on borrowings								1.50%
Tranche B-3 Facility [Member] \| Eurodollar [Member]
Debt Instrument [Line Items]
Interest on borrowings								2.50%
Basis spread on variable rate								1.00%
Tranche B-3 Facility [Member] \| Base Rate Loans [Member]
Debt Instrument [Line Items]
Interest on borrowings								1.50%
Basis spread on variable rate								0.50%
Tranche B-3 Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Interest on borrowings								0.75%
Amended and Restated Senior Credit Facility [Member]
Debt Instrument [Line Items]
Date entered into an agreement					Dec. 31, 2012	Apr. 01, 2011
Amount available under revolving line of credit								$ 485,000
Debt instrument maturity date				Nov. 30, 2021										Feb. 11, 2022
Term loan repayments													$ 1,200
Amended and Restated Senior Credit Facility [Member] \| Eurodollar [Member]
Debt Instrument [Line Items]
Basis spread on variable rate								1.00%
Amended and Restated Senior Credit Facility [Member] \| Base Rate Loans [Member]
Debt Instrument [Line Items]
Basis spread on variable rate								0.50%
Amended and Restated Senior Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Interest on borrowings								2.50%
Amended and Restated Senior Credit Facility [Member] \| Tranche B-3 Facility [Member]
Debt Instrument [Line Items]
Term loan repayments														$ 447,300
Amended and Restated Senior Credit Facility [Member] \| Tranche B-4 Facilities [Member]
Debt Instrument [Line Items]
Debt instrument maturity date								Feb. 16, 2023
Term loan repayments								$ 854,400
Amended and Restated Senior Credit Facility [Member] \| Tranche B-4 Facilities [Member] \| Eurodollar [Member]
Debt Instrument [Line Items]
Interest on borrowings								2.50%
Basis spread on variable rate								1.00%
Amended and Restated Senior Credit Facility [Member] \| Tranche B-4 Facilities [Member] \| Base Rate Loans [Member]
Debt Instrument [Line Items]
Interest on borrowings								1.50%
Basis spread on variable rate								0.50%
Amended and Restated Senior Credit Facility [Member] \| Tranche B-4 Facilities [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Interest on borrowings								0.75%
Amended and Restated Senior Credit Facility [Member] \| June 30, 2020 to December 31, 2020 [Member]
Debt Instrument [Line Items]
Term loan principal repayments				$ 7,100
Term loan repayments										$ 1,200
Amended and Restated Senior Credit Facility [Member] \| March 31, 2021 to September 30, 2021 [Member]
Debt Instrument [Line Items]
Term loan principal repayments				$ 9,500
Amended and Restated Senior Credit Facility [Member] \| March 31, 2019 to December 31, 2019 [Member]
Debt Instrument [Line Items]
Term loan repayments												$ 1,200
Amended and Restated Senior Credit Facility [Member] \| September 30, 2015 to December 31, 2015 [Member]
Debt Instrument [Line Items]
Term loan repayments											$ 1,200
Amended and Restated Senior Credit Facility [Member] \| Standby Letters Of Credit [Member]
Debt Instrument [Line Items]
Standby letters of credit outstanding								$ 15,000
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member]
Debt Instrument [Line Items]
Term loan repayments													$ 2,300
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member] \| June 30, 2020 to December 31, 2020 [Member]
Debt Instrument [Line Items]
Term loan repayments										$ 2,300
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member] \| March 31, 2019 to December 31, 2019 [Member]
Debt Instrument [Line Items]
Term loan repayments												$ 2,300
Amended and Restated Senior Credit Facility [Member] \| TLB Facility Due on February 16, 2023 [Member] \| September 30, 2015 to December 31, 2015 [Member]
Debt Instrument [Line Items]
Term loan repayments											$ 2,300
Amended and Restated Senior Credit Facility [Member] \| Subsequent Event [Member]
Debt Instrument [Line Items]
Borrowings on revolving credit facility							$ 100,000
Eleventh Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement			Feb. 06, 2019
Twelfth Amendment [Member]
Debt Instrument [Line Items]
Date entered into an agreement		Feb. 27, 2019
Thirteenth Amendment [Member] \| Subsequent Event [Member]
Debt Instrument [Line Items]
Date entered into an agreement	Apr. 21, 2020

Long-Term Debt (6.125% Senior Notes due 2021) - Additional Information (Detail) - 6.125% Senior Notes Due 2021 [Member] - USD ($)		3 Months Ended
	Mar. 12, 2013	Mar. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Issued Senior Notes	$ 150,000,000.0
Debt instrument interest rate	6.125%	6.125%	6.125%
Debt instrument maturity date	Mar. 15, 2021
Interest on the notes		payable semi-annually in arrears on March 15 and September 15 of each year

Long-Term Debt (5.125% Senior Notes due 2022) - Additional Information (Detail) - 5.125% Senior Notes Due 2022 [Member] - USD ($)		3 Months Ended
	Jul. 01, 2014	Mar. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Issued Senior Notes	$ 300,000,000.0
Debt instrument interest rate	5.125%	5.125%	5.125%
Debt instrument maturity date	Jul. 01, 2022
Interest on the notes		payable semi-annually in arrears on January 1 and July 1 of each year

Long-Term Debt (5.625% Senior Notes due 2023) - Additional Information (Detail) - 5.625% Senior Notes Due 2023 [Member] - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Sep. 21, 2015	Feb. 11, 2015
Debt Instrument [Line Items]
Issued Senior Notes			$ 275,000,000.0	$ 375,000,000.0
Debt instrument interest rate	5.625%	5.625%	5.625%	5.625%
Senior Notes	$ 650,000,000	$ 650,000,000	$ 650,000,000.0
Debt instrument maturity date	Feb. 15, 2023
Interest on the notes	payable semi-annually in arrears on February 15 and August 15 of each year

Long-Term Debt (6.500% Senior Notes due 2024) - Additional Information (Detail) - 6.500% Senior Notes Due 2024 [Member] - USD ($)		3 Months Ended
	Feb. 16, 2016	Mar. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Issued Senior Notes	$ 390,000,000.0
Debt instrument interest rate	6.50%	6.50%	6.50%
Debt instrument maturity date	Mar. 01, 2024
Interest on the notes		payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2016

Equity-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized common stock	8,200,000
Annual increments in employee grants	25.00%
Equity incentive plan available for future grant	1,024,052
Stock options, contractual term	10 years
Equity-based compensation expense	$ 4,979,000	$ 6,101,000
Unrecognized compensation expense related to unvested options	$ 50,800,000
Vesting period	1 year 6 months
Warrant outstanding	$ 0
Deferred income tax benefit	11,286,000	(666,000)
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred income tax benefit	$ 1,300,000	$ 1,600,000
Restricted Stock Award [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Restricted Stock Award [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Restricted Stock Units [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	2 years
Number of shares issuable at the end of the vesting period, percentage	0.00%
Restricted Stock Units [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Number of shares issuable at the end of the vesting period, percentage	200.00%

Equity-Based Compensation - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding, Beginning balance	1,360,068	1,199,540
Options granted	443,200	605,200
Options exercised		(55,671)
Options cancelled	(105,462)	(389,001)
Options outstanding, Ending balance	1,697,806	1,360,068	1,199,540
Options exercisable, Ending balance	702,956	513,290
Options outstanding, Weighted Average Exercise Price, Beginning balance	$ 39.40	$ 44.64
Options granted, Weighted Average Exercise Price	33.72	28.50
Options exercised, Weighted Average Exercise Price		19.05
Options cancelled, Weighted Average Exercise Price	41.00	40.84
Options outstanding, Weighted Average Exercise Price, Ending balance	37.81	39.40	$ 44.64
Options exercisable, Weighted Average Exercise Price, Ending balance	$ 44.08	$ 48.08
Options outstanding, Weighted Average Remaining Contractual Term	7 years 11 months 19 days	7 years 6 months 25 days	7 years 3 months 3 days
Options granted, Weighted Average Remaining Contractual Term	9 years 10 months 28 days	9 years 2 months 15 days
Options exercisable, Weighted Average Remaining Contractual Term, Ending balance	6 years 4 months 9 days	5 years 10 months 17 days
Options outstanding, Aggregate Intrinsic Value	$ 659	$ 1,650	$ 2,717
Options granted, Aggregate Intrinsic Value		1,343
Options exercised, Aggregate Intrinsic Value		658
Options cancelled, Aggregate Intrinsic Value	0	0
Options exercisable, Aggregate Intrinsic Value, Ending balance	$ 479	$ 512

Equity-Based Compensation - Schedule of Stock Options Valuation Assumptions (Detail) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant-date fair value of options	$ 12.29	$ 17.59
Risk-free interest rate	1.60%	2.40%
Expected volatility	39.00%	38.00%
Expected life (in years)	5 years	5 years

Equity-Based Compensation - Restricted Stock Activity (Detail) - Restricted Stock Award [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	805,136	805,057
Granted, Number of Shares	511,006	700,937
Cancelled, Number of Shares	(57,782)	(389,684)
Vested, Number of Shares	(160,398)	(311,174)
Unvested, Number of Shares/Units, Ending balance	1,097,962	805,136
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 34.14	$ 42.40
Granted, Weighted Average Grant-Date Fair Value	25.37	28.77
Cancelled, Weighted Average Grant-Date Fair Value	35.55	33.50
Vested, Weighted Average Grant-Date Fair Value	36.73	44.23
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 29.61	$ 34.14

Equity-Based Compensation - Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested, Number of Shares/Units, Beginning balance	447,357	484,111
Granted, Number of Units	583,680	234,408
Cancelled, Number of Units	(10,123)	(271,162)
Vested, Number of Units	(12,691)
Unvested, Number of Shares/Units, Ending balance	1,008,223	447,357
Unvested, Weighted Average Grant-Date Fair Value, Beginning balance	$ 38.89	$ 44.52
Granted, Weighted Average Grant-Date Fair Value	10.60	34.54
Cancelled, Weighted Average Grant-Date Fair Value	42.09	45.17
Vested, Weighted Average Grant-Date Fair Value	42.09
Unvested, Weighted Average Grant-Date Fair Value, Ending balance	$ 22.44	$ 38.89

Income Taxes - Additional Information (Detail)	3 Months Ended
Income Taxes - Additional Information (Detail)	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Effective tax rates	14.50%	20.00%

Derivatives - Additional Information (Detail)	1 Months Ended
Derivatives - Additional Information (Detail)	Aug. 31, 2019 USD ($)	Aug. 31, 2019 GBP (£)	Mar. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Aug. 31, 2019 GBP (£)	May 31, 2016 USD ($)	May 31, 2016 GBP (£)
Derivative [Line Items]
Cross currency swap liabilities			$ (9,000,000.0)	$ (68,900,000)
Cross Currency Swap Assets [Member]
Derivative [Line Items]
Notional amount	$ 650,000,000.0				£ 538,100,000	$ 650,000,000.0	£ 449,300,000
Terminated cross currency swap derivatives	105,000,000.0
Cross currency swap agreement cash flow due to interest payment	$ 35,800,000	£ 25,400,000

Fair Value Measurements - Carrying Amounts and Fair Values of Company's Amended and Restated Senior Credit Facilities and Contingent Consideration Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other long-term debt	$ 4,533	$ 4,821
Carrying Amount [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other long-term debt	4,533	4,821
Derivative instrument liabilities	(9,015)	(68,915)
Carrying Amount [Member] \| Amended and Restated Senior Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Secured	1,659,098	1,668,062
Carrying Amount [Member] \| 6.125% Senior Notes Due 2021 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	149,409	149,254
Carrying Amount [Member] \| 5.125% Senior Notes Due 2022 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	297,973	297,761
Carrying Amount [Member] \| 5.625% Senior Notes Due 2023 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	645,156	644,771
Carrying Amount [Member] \| 6.500% Senior Notes due 2024 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	384,723	384,430
Fair Value [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other long-term debt	4,533	4,821
Derivative instrument liabilities	(9,015)	(68,915)
Fair Value [Member] \| Amended and Restated Senior Credit Facility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Amended and Restated Senior Credit Facility	1,659,098	1,668,062
Fair Value [Member] \| 6.125% Senior Notes Due 2021 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	144,927	149,441
Fair Value [Member] \| 5.125% Senior Notes Due 2022 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	283,998	299,994
Fair Value [Member] \| 5.625% Senior Notes Due 2023 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	607,995	655,249
Fair Value [Member] \| 6.500% Senior Notes due 2024 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	$ 374,143	$ 398,366

Fair Value Measurements - Additional Information (Detail)	Mar. 31, 2020	Dec. 31, 2019	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%					6.125%
5.125% Senior Notes Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.125%	5.125%				5.125%
5.625% Senior Notes Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	5.625%	5.625%		5.625%	5.625%
6.500% Senior Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.50%	6.50%	6.50%

Commitments and Contingencies - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2020 USD ($)
Loss Contingencies [Line Items]
Maximum professional liability aggregate policy limit	$ 75,000,000.0
Maximum [Member]
Loss Contingencies [Line Items]
Maximum self insured professional liability limit per claim	3,000,000.0
Minimum [Member]
Loss Contingencies [Line Items]
Maximum professional liability retention limit	$ 3,000,000.0

Noncontrolling Interests - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2020 Facility
Noncontrolling Interest [Line Items]
Number of facilities operated by non-wholly owned subsidiaries	5
Non-Wholly Owned Subsidiaries [Member] \| Minimum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	60.00%
Non-Wholly Owned Subsidiaries [Member] \| Maximum [Member]
Noncontrolling Interest [Line Items]
Equity ownership interests percentage in the facility	86.00%

Noncontrolling Interests - Summary of Redeemable Noncontrolling Interests (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($)
Noncontrolling Interest [Abstract]
Beginning Balance	$ 33,151
Net income attributable to noncontrolling interests	604
Dividend payments to noncontrolling interests	(264)
Ending Balance	$ 33,491

Other Current Assets - Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid expenses	$ 22,161	$ 23,708
Cost report receivable	14,402	13,723
Other receivables	14,257	16,097
Workers’ compensation deposits – current portion	10,000	10,000
Income taxes receivable	9,358	5,579
Insurance receivable – current portion	5,739	3,030
Inventory	4,882	4,759
Other	1,644	1,348
Other current assets	$ 82,443	$ 78,244

Other Accrued Liabilities - Summary of Other Accrued Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accounts Payable And Accrued Liabilities Current [Abstract]
Accrued expenses	$ 41,131	$ 50,614
Unearned income	31,631	38,475
Accrued interest	11,660	33,323
Finance lease liabilities	6,637	6,819
Insurance liability – current portion	4,731	4,731
Accrued property taxes	4,222	4,755
Other	4,346	2,443
Other accrued liabilities	$ 104,358	$ 141,160

Segment Information - Additional Information (Detail)	3 Months Ended
Segment Information - Additional Information (Detail)	Mar. 31, 2020 Facility Bed State
Segment Reporting Information [Line Items]
Number of facilities \| Facility	588
Number of beds \| Bed	18,200
Number of operating states \| State	40
U.S. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities \| Facility	228
Number of beds \| Bed	9,600
Number of operating states \| State	40
U.K. Facilities [Member]
Segment Reporting Information [Line Items]
Number of facilities \| Facility	360
Number of beds \| Bed	8,700

Segment Information - Summary of Reconciliation of Segment EBITDA to Income before Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Revenue	$ 782,810	$ 760,617
Segment EBITDA	132,849	136,003
Equity-based compensation expense	(4,979)	(6,101)
Transaction-related expenses	(3,549)	(4,321)
Interest expense, net	(42,785)	(48,130)
Depreciation and amortization	(41,680)	(40,580)
Income before income taxes	39,856	36,871
U.S. Facilities [Member]
Segment Reporting Information [Line Items]
Revenue	509,217	487,960
U.S. Facilities [Member] \| Operating Segment [Member]
Segment Reporting Information [Line Items]
Revenue	509,217	487,960
Segment EBITDA	120,074	119,008
U.K. Facilities [Member]
Segment Reporting Information [Line Items]
Revenue	273,593	272,657
U.K. Facilities [Member] \| Operating Segment [Member]
Segment Reporting Information [Line Items]
Revenue	273,593	272,657
Segment EBITDA	36,168	40,056
Corporate and Other [Member] \| Corporate Reconciling Items and Eliminations [Member]
Segment Reporting Information [Line Items]
Segment EBITDA	$ (23,393)	$ (23,061)

Segment Information - Summary of Financial Information by Operating Segment, Goodwill (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($)
Goodwill:
Goodwill	$ 2,775,006
Accumulated impairment loss	(325,875)
Net goodwill, beginning balance	2,449,131
Prior period purchase price adjustments	(13)
Foreign currency translation gain	(22,418)
Goodwill	2,752,575
Accumulated impairment loss	(325,875)
Net goodwill, ending balance	2,426,700
U.S. Facilities [Member] \| Operating Segment [Member]
Goodwill:
Goodwill	2,085,104
Net goodwill, beginning balance	2,085,104
Prior period purchase price adjustments	(13)
Goodwill	2,085,091
Net goodwill, ending balance	2,085,091
U.K. Facilities [Member] \| Operating Segment [Member]
Goodwill:
Goodwill	689,902
Accumulated impairment loss	(325,875)
Net goodwill, beginning balance	364,027
Foreign currency translation gain	(22,418)
Goodwill	667,484
Accumulated impairment loss	(325,875)
Net goodwill, ending balance	$ 341,609

Segment Information - Summary of Financial Information by Operating Segment, Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Assets:
Assets	$ 6,717,995	$ 6,879,142
U.S. Facilities [Member] \| Operating Segment [Member]
Assets:
Assets	4,083,825	4,037,968
U.K. Facilities [Member] \| Operating Segment [Member]
Assets:
Assets	2,443,498	2,610,357
Corporate and Other [Member] \| Corporate Reconciling Items and Eliminations [Member]
Assets:
Assets	$ 190,672	$ 230,817

Segment Information - Summary of Financial Information by Operating Segment, Assets (Parenthetical) (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 3,151,739	$ 3,224,034
Operating Segment [Member] \| U.S. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	1,500,000	1,400,000
Operating Segment [Member] \| U.K. Facilities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	1,600,000	1,700,000
Corporate Reconciling Items and Eliminations [Member] \| Corporate and Other [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property and equipment, net	$ 57,300	$ 50,900

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 2,505,381	$ 2,333,307
Foreign currency translation (loss) gain	(122,000)	44,481
Gain on derivative instruments, net of tax of $16.3 million	43,746	(8,690)
Balance	2,464,167	2,403,343
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(434,633)
Foreign currency translation (loss) gain	(122,321)
Balance	(556,954)
Change in Fair Value of Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	24,958
Gain on derivative instruments, net of tax of $16.3 million	43,746
Balance	68,704
Pension Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(5,209)
Foreign currency translation (loss) gain	321
Balance	(4,888)
Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(414,884)	(462,377)
Balance	$ (493,138)	$ (426,586)

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accumulated Other Comprehensive Income Loss Net Of Tax [Abstract]
Gain on derivative instruments, tax	$ 16.3	$ (3.5)

Financial Information for the Company and Its Subsidiaries - Additional Information (Detail)	Mar. 31, 2020	Dec. 31, 2019	Feb. 16, 2016	Sep. 21, 2015	Feb. 11, 2015	Jul. 01, 2014	Mar. 12, 2013
6.125% Senior Notes Due 2021 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.125%	6.125%					6.125%
5.125% Senior Notes Due 2022 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.125%	5.125%				5.125%
5.625% Senior Notes Due 2023 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	5.625%	5.625%		5.625%	5.625%
6.500% Senior Notes Due 2024 [Member]
Line of Credit Facility [Line Items]
Debt instrument interest rate	6.50%	6.50%	6.50%

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Balance Sheets (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 81,004	$ 124,192
Accounts receivable, net	339,505	339,775
Other current assets	82,443	78,244
Total current assets	502,952	542,211
Property and equipment, net	3,151,739	3,224,034
Goodwill	2,426,700	2,449,131
Intangible assets, net	89,052	90,357
Deferred tax assets	3,307	3,339
Operating lease right-of-use assets	476,028	501,837
Other assets	68,217	68,233
Total assets	6,717,995	6,879,142
Current liabilities:
Current portion of long-term debt	196,072	43,679
Accounts payable	134,693	127,045
Accrued salaries and benefits	114,790	122,552
Current portion of operating lease liabilities	29,671	29,140
Other accrued liabilities	104,358	141,160
Total current liabilities	579,584	463,576
Long-term debt	2,944,820	3,105,420
Deferred tax liabilities	85,405	71,860
Operating lease liabilities	474,746	502,252
Derivative instrument liabilities	9,015	68,915
Other liabilities	126,767	128,587
Total liabilities	4,220,337	4,340,610
Redeemable noncontrolling interests	33,491	33,151
Total equity	2,464,167	2,505,381	$ 2,420,691	$ 2,422,346	$ 2,403,343	$ 2,333,307
Total liabilities and equity	6,717,995	6,879,142
Parent [Member]
Current assets:
Deferred tax assets	1,303	1,403
Investment in subsidiaries	5,390,417	5,521,340
Other assets	234,014	233,975
Total assets	5,625,734	5,756,718
Current liabilities:
Current portion of long-term debt	196,072	43,679
Other accrued liabilities	11,660	33,323
Total current liabilities	207,732	77,002
Long-term debt	2,944,820	3,105,420
Derivative instrument liabilities	9,015	68,915
Total liabilities	3,161,567	3,251,337
Total equity	2,464,167	2,505,381
Total liabilities and equity	5,625,734	5,756,718
Combined Subsidiary Guarantors [Member]
Current assets:
Cash and cash equivalents	51,340	98,943
Accounts receivable, net	272,098	266,864
Other current assets	65,346	61,508
Total current assets	388,784	427,315
Property and equipment, net	1,348,045	1,313,830
Goodwill	1,992,332	1,992,344
Intangible assets, net	58,312	58,291
Operating lease right-of-use assets	98,166	97,396
Other assets	48,597	48,949
Total assets	3,934,236	3,938,125
Current liabilities:
Accounts payable	97,196	87,165
Accrued salaries and benefits	82,072	89,483
Current portion of operating lease liabilities	18,571	17,967
Other accrued liabilities	26,021	22,672
Total current liabilities	223,860	217,287
Deferred tax liabilities	41,087	21,858
Operating lease liabilities	85,577	85,365
Other liabilities	110,923	110,445
Total liabilities	461,447	434,955
Total equity	3,472,789	3,503,170
Total liabilities and equity	3,934,236	3,938,125
Combined Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	29,664	25,249
Accounts receivable, net	67,407	72,911
Other current assets	17,097	16,736
Total current assets	114,168	114,896
Property and equipment, net	1,803,694	1,910,204
Goodwill	434,368	456,787
Intangible assets, net	30,740	32,066
Deferred tax assets	3,307	3,339
Operating lease right-of-use assets	377,862	404,441
Other assets	12,214	13,127
Total assets	2,776,353	2,934,860
Current liabilities:
Accounts payable	37,497	39,880
Accrued salaries and benefits	32,718	33,069
Current portion of operating lease liabilities	11,100	11,173
Other accrued liabilities	66,677	85,165
Total current liabilities	147,992	169,287
Long-term debt	226,608	227,818
Deferred tax liabilities	45,621	51,405
Operating lease liabilities	389,169	416,887
Other liabilities	15,844	18,142
Total liabilities	825,234	883,539
Redeemable noncontrolling interests	33,491	33,151
Total equity	1,917,628	2,018,170
Total liabilities and equity	2,776,353	2,934,860
Consolidating Adjustments [Member]
Current assets:
Deferred tax assets	(1,303)	(1,403)
Investment in subsidiaries	(5,390,417)	(5,521,340)
Other assets	(226,608)	(227,818)
Total assets	(5,618,328)	(5,750,561)
Current liabilities:
Long-term debt	(226,608)	(227,818)
Deferred tax liabilities	(1,303)	(1,403)
Total liabilities	(227,911)	(229,221)
Total equity	(5,390,417)	(5,521,340)
Total liabilities and equity	$ (5,618,328)	$ (5,750,561)

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019
Condensed Financial Statements, Captions [Line Items]
Revenue	$ 782,810				$ 760,617
Salaries, wages and benefits	440,316				429,579
Professional fees	63,300				57,007
Supplies	31,971				29,957
Rents and leases	20,824				20,307
Other operating expenses	98,529				93,865
Depreciation and amortization	41,680				40,580
Interest expense, net	42,785				48,130
Transaction-related expenses	3,549				4,321
Total expenses	742,954				723,746
(Loss) income before income taxes	39,856				36,871
(Benefit from) provision for income taxes	5,789				7,360
Net income	34,067				29,511
Net income attributable to noncontrolling interests	(604)				(40)
Net income attributable to Acadia Healthcare Company, Inc.	33,463	$ (11,254)	$ 42,566	$ 48,140	29,471
Other comprehensive income:
Foreign currency translation (loss) gain	(122,000)				44,481
Loss on derivative instruments	43,746				(8,690)
Other comprehensive (loss) income	(78,254)	$ 93,110	$ (48,377)	$ (33,031)	35,791
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.	(44,791)				65,262
Parent [Member]
Condensed Financial Statements, Captions [Line Items]
Salaries, wages and benefits	4,979				6,101
Interest expense, net	14,460				19,578
Total expenses	19,439				25,679
(Loss) income before income taxes	(19,439)				(25,679)
Equity in earnings of subsidiaries	48,353				48,157
(Benefit from) provision for income taxes	(5,153)				(7,033)
Net income	34,067				29,511
Net income attributable to Acadia Healthcare Company, Inc.	34,067				29,511
Other comprehensive income:
Loss on derivative instruments	43,746				(8,690)
Other comprehensive (loss) income	43,746				(8,690)
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.	77,813				20,821
Combined Subsidiary Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue	474,612				459,818
Salaries, wages and benefits	261,603				254,942
Professional fees	28,558				25,368
Supplies	20,859				19,384
Rents and leases	8,883				8,403
Other operating expenses	63,819				59,390
Depreciation and amortization	21,046				19,605
Interest expense, net	24,159				23,018
Transaction-related expenses	1,525				3,218
Total expenses	430,452				413,328
(Loss) income before income taxes	44,160				46,490
(Benefit from) provision for income taxes	11,712				17,065
Net income	32,448				29,425
Net income attributable to Acadia Healthcare Company, Inc.	32,448				29,425
Other comprehensive income:
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.	32,448				29,425
Combined Non-Guarantors [Member]
Condensed Financial Statements, Captions [Line Items]
Revenue	308,198				300,799
Salaries, wages and benefits	173,734				168,536
Professional fees	34,742				31,639
Supplies	11,112				10,573
Rents and leases	11,941				11,904
Other operating expenses	34,710				34,475
Depreciation and amortization	20,634				20,975
Interest expense, net	4,166				5,534
Transaction-related expenses	2,024				1,103
Total expenses	293,063				284,739
(Loss) income before income taxes	15,135				16,060
(Benefit from) provision for income taxes	(770)				(2,672)
Net income	15,905				18,732
Net income attributable to noncontrolling interests	(604)				(40)
Net income attributable to Acadia Healthcare Company, Inc.	15,301				18,692
Other comprehensive income:
Foreign currency translation (loss) gain	(122,000)				44,481
Other comprehensive (loss) income	(122,000)				44,481
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.	(106,699)				63,173
Consolidating Adjustments [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in earnings of subsidiaries	(48,353)				(48,157)
Net income	(48,353)				(48,157)
Net income attributable to Acadia Healthcare Company, Inc.	(48,353)				(48,157)
Other comprehensive income:
Comprehensive (loss) income attributable to Acadia Healthcare Company, Inc.	$ (48,353)				$ (48,157)

Financial Information for the Company and Its Subsidiaries - Summary of Condensed Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating activities:
Net income (loss)	$ 34,067	$ 29,511
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Depreciation and amortization	41,680	40,580
Amortization of debt issuance costs	3,050	2,888
Equity-based compensation expense	4,979	6,101
Deferred income taxes	11,286	(666)
Other	(107)	2,187
Change in operating assets and liabilities:
Accounts receivable, net	(2,828)	(11,980)
Other current assets	(19,131)	(5,875)
Other assets	(1,096)	295
Accounts payable and other accrued liabilities	(21,755)	(15,701)
Accrued salaries and benefits	(6,030)	(5,849)
Other liabilities	1,431	2,182
Net cash provided by operating activities	45,546	43,673
Investing activities:
Cash paid for acquisitions, net of cash acquired		(40,400)
Cash paid for capital expenditures	(69,547)	(69,248)
Cash paid for real estate acquisitions	(3,149)	(1,066)
Proceeds from sale of property and equipment	207	928
Other	(1,672)	(315)
Net cash used in investing activities	(74,161)	(110,101)
Financing activities:
Borrowings on revolving credit facility		71,573
Principal payments on long-term debt	(10,621)	(8,246)
Common stock withheld for minimum statutory taxes, net	(1,402)	(1,327)
Distributions to noncontrolling interests	(264)
Other	(1,143)	(3,497)
Net cash (used in) provided by financing activities	(13,430)	58,503
Effect of exchange rate changes on cash	(1,143)	1,099
Net decrease in cash and cash equivalents	(43,188)	(6,826)
Cash and cash equivalents at beginning of the period	124,192	50,510
Cash and cash equivalents at end of the period	81,004	43,684
Parent [Member]
Operating activities:
Net income (loss)	34,067	29,511
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Equity in earnings of subsidiaries	(48,353)	(48,157)
Amortization of debt issuance costs	3,050	2,888
Equity-based compensation expense	4,979	6,101
Deferred income taxes	101	(254)
Other	(101)	1,993
Change in operating assets and liabilities:
Other assets	82	2,665
Net cash provided by operating activities	(6,175)	(5,253)
Financing activities:
Borrowings on revolving credit facility		71,573
Principal payments on long-term debt	(10,621)	(8,246)
Common stock withheld for minimum statutory taxes, net	(1,402)	(1,327)
Other		(2,375)
Cash provided by (used in) intercompany activity	18,198	(54,372)
Net cash (used in) provided by financing activities	6,175	5,253
Combined Subsidiary Guarantors [Member]
Operating activities:
Net income (loss)	32,448	29,425
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Depreciation and amortization	21,046	19,605
Deferred income taxes	11,044	(678)
Other	(9)	253
Change in operating assets and liabilities:
Accounts receivable, net	(5,234)	(15,693)
Other current assets	(17,887)	(5,484)
Other assets	(1,593)	(353)
Accounts payable and other accrued liabilities	17,726	(7,100)
Accrued salaries and benefits	(7,411)	(7,872)
Other liabilities	2,803	3,317
Net cash provided by operating activities	52,933	15,420
Investing activities:
Cash paid for acquisitions, net of cash acquired		(40,400)
Cash paid for capital expenditures	(48,264)	(45,231)
Cash paid for real estate acquisitions	(3,149)	(1,066)
Proceeds from sale of property and equipment	207	836
Other	(1,672)	(315)
Net cash used in investing activities	(52,878)	(86,176)
Financing activities:
Other	(423)	(442)
Cash provided by (used in) intercompany activity	(47,235)	56,570
Net cash (used in) provided by financing activities	(47,658)	56,128
Net decrease in cash and cash equivalents	(47,603)	(14,628)
Cash and cash equivalents at beginning of the period	98,943	32,471
Cash and cash equivalents at end of the period	51,340	17,843
Combined Non-Guarantors [Member]
Operating activities:
Net income (loss)	15,905	18,732
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Depreciation and amortization	20,634	20,975
Deferred income taxes	141	266
Other	3	(59)
Change in operating assets and liabilities:
Accounts receivable, net	2,406	3,713
Other current assets	(1,244)	(391)
Other assets	497	648
Accounts payable and other accrued liabilities	(39,481)	(8,601)
Accrued salaries and benefits	1,381	2,023
Other liabilities	(1,372)	(1,135)
Net cash provided by operating activities	(1,130)	36,171
Investing activities:
Cash paid for capital expenditures	(21,283)	(24,017)
Proceeds from sale of property and equipment		92
Net cash used in investing activities	(21,283)	(23,925)
Financing activities:
Principal payments on long-term debt	(82)	(2,665)
Distributions to noncontrolling interests	(264)
Other	(720)	(680)
Cash provided by (used in) intercompany activity	29,037	(2,198)
Net cash (used in) provided by financing activities	27,971	(5,543)
Effect of exchange rate changes on cash	(1,143)	1,099
Net decrease in cash and cash equivalents	4,415	7,802
Cash and cash equivalents at beginning of the period	25,249	18,039
Cash and cash equivalents at end of the period	29,664	25,841
Consolidating Adjustments [Member]
Operating activities:
Net income (loss)	(48,353)	(48,157)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Equity in earnings of subsidiaries	48,353	48,157
Change in operating assets and liabilities:
Other assets	(82)	(2,665)
Net cash provided by operating activities	(82)	(2,665)
Financing activities:
Principal payments on long-term debt	82	2,665
Net cash (used in) provided by financing activities	$ 82	$ 2,665

Subsequent Events - Additional Information (Detail) - USD ($) $ in Thousands				1 Months Ended	3 Months Ended
	Apr. 21, 2020	Dec. 31, 2012	Apr. 01, 2011	Apr. 30, 2020	Mar. 31, 2019
Subsequent Event [Line Items]
Borrowings on revolving credit facility					$ 71,573
Subsequent Event [Member] \| CARES Act [Member]
Subsequent Event [Line Items]
Offer of eligible relief amount				$ 100,000,000
Received relief amount				$ 20,000
Subsequent Event [Member] \| CARES Act [Member] \| CMS’ Accelerated and Advance Payment Program [Member] \| Medicare [Member]
Subsequent Event [Line Items]
Period of amount payable in advance				3 months
Repayment of advanced payments description				The repayment of these accelerated/advanced payments does not begin until 120 days after the date of the issuance of the payment. Once the repayment period starts, the amounts previously advanced to the provider or supplier will be recouped from the provider’s or supplier’s new Medicare claims. Facilities will generally have 210 days from the date the accelerated or advance payment was made to repay the amounts that they owe. The Company applied for and received approximately $45 million in April 2020 from this program, which the Company expects to repay over a three-month period from August to November 2020.
Amount of advance payment received				$ 45,000
Expected repayment period				3 months
Subsequent Event [Member] \| CARES Act [Member] \| CMS’ Accelerated and Advance Payment Program [Member] \| Medicare [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Percentage of amount payable in advance				100.00%
Amended and Restated Senior Credit Facility [Member]
Subsequent Event [Line Items]
Date entered into an agreement		Dec. 31, 2012	Apr. 01, 2011
Amended and Restated Senior Credit Facility [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Borrowings on revolving credit facility				$ 100,000
Thirteenth Amendment [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Date entered into an agreement	Apr. 21, 2020